  
 
Protocol Date: Jan.18. 2012          Version 1.0  1  
ISCHEMIA Trial Protocol  
International S tudy of C omparative Health E ffectiveness 
with M edical and Invasive Approaches  
Sponsor:  National Heart, Lung, and Blood Institute (NHLBI)  
 
Study Chair   
Judith S. Hochman, MD  
 
 
Study Co -Chair    
David J. Maron, MD  
 
Clinical Coordinating Center  Cardiovascular Clinical Research Center  
[LOCATION_001] University School of Medicine  
  
  
Statistical and Data Coordinating 
Center  
  Duke Clinical Research Institute  
Protocol Version Date:          January 18, 2012   
  
 
Protocol Date: Jan.18. 2012          Version 1.0  2 PROTOCOL VERSION AND AMENDMENT TRACKING  
 
Version Number/Amendment  Approval Date  
  
  
  
  
 
  
  
 
Protocol Date: Jan.18. 2012          Version 1.0  3  
Protocol Signature [CONTACT_289932], and provides 
the necessary assurances that this trial will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable regulations and ICH guidelines.  
Version Date:  January 18, 2012  
 
_________________________________  _________________________ 
Signature [CONTACT_789]                            [CONTACT_1782]  
 
_________________________________   
Printed Name [CONTACT_789]                       
 
_________________________________   
Name [CONTACT_4004]  
 
_________________________________   
Location of Facility (City, Country)  
 
 
  
 
Protocol Date: Jan.18. 2012          Version 1.0  4 CLINICAL TRIAL SUM MARY   
Title International Study of Comparative Health Effectiveness with Medical and 
Invasive Approaches  
Study Objectives  Primary objective  is to determine whether an invasive (INV) strategy of 
routine early cardiac catheterization with intent for optimal 
revascularization in addition to optimal medical therapy in patients with stable ischemic heart disease ( SIHD ) and at least moderate ischem ia on 
stress imaging reduces the incidence of the composite of cardiovascular death or nonfatal myocardial infarction compared with a conservative (CON) strategy of optimal medical therapy alone with cardiac 
catheterization and revascularization reserved f or patients with refractory 
angina, acute coronary syndrome, acute ischemic heart failure or 
resuscitated cardiac arrest.  
Secondary objective is to determine whether an INV strategy is more 
effective than CON strategy in improving angina control, as asses sed by 
[CONTACT_345500] (SAQ) Angina Frequency scale, and 
disease- specific quality of life, as assessed by [CONTACT_587864].  
Other secondary objectives include comparing the incidence of the 
composite of cardiovascular death, nonfatal myocardial infarction, resuscitated cardiac arrest, or hospi[INVESTIGATOR_587837]; individual components of this endpoint; all -cause death; stroke; as 
well as comparing health resource utilization, cost, and cost -effectiv eness 
between the two randomized strategies.  
Study Design  ISCHEMIA is an international comparative effectiveness study. 
Participants will be recruited following clinically indicated stress testing but 
before catheterization and randomized in a 1:1 fashion to an INV or CON 
strategy.  
Number of 
Participant s Approximately 8,000 participant s randomized  
Trial Location  Multinational: approximately 500 sites worldwide  
Inclusion Criteria  • At least moderate ischemia on a stress imaging  test with nuclear 
myocardial perfusion (≥10% myocardium), echo or cardiac magnetic resonance wall motion (≥3/16 segments with stress -induced severe 
hypokinesis or akinesis), or cardiac magnetic resonance perfusion 
(≥12% myocardium).  
• Participant  is willing  to comply with all aspects of the protocol, including 
  
 
Protocol Date: Jan.18. 2012          Version 1.0  5 adherence to medical therapy and follow -up visits  
• Participant  is willing to give written informed consent  
• Age ≥ 21 years  
Exclusion Criteria  • LVEF < 35%  
• History of unprotected left main stenosis >50% on prior coronary 
computed tomography angiography (CCTA) or prior cardiac 
catheterization (if available).  
• Finding of “no obstructive CAD” (<50% stenosis in all major epi[INVESTIGATOR_218709]) on prior CCTA or prior catheterization, performed within 12 
months  
• Prior known coronary anatomy unsuitable for either PCI or CABG  
• Unacceptable level of angina despi[INVESTIGATOR_133349]  
• Very dissatisfied with medical management of angina  
• History of noncompliance with medical therapy  
• Acute coronary syndrome within the previous 2 months  
• PCI or CABG within the previous 12 months  
• Stroke within the previous 6 months or intracranial hemorrhage at any 
time 
• History of ventricular tachycardia requiring therapy for termination, or 
symptomatic sustained ventricular tachycardia  
• NYHA class III -IV heart failure at entry or hospi[INVESTIGATOR_587838] 6 months  
• Non-ischemic dilated or hypertrophic cardiomyopathy  
• End stage renal disease on dialysis or estimated glomerular f iltration 
rate (eGFR) <30mL/min  
• Severe valvular disease or valvular disease likely to require surgery 
within 5  years  
• Allergy to radiographic contrast that cannot be adequately pre-
medicated, or any prior anaphylaxis to radiographic contrast  
• Planned major s urgery necessitating interruption of dual antiplatelet 
therapy   
• Life expectancy less than 5 years due to non -cardiovascular 
comorbidity  
  
 
Protocol Date: Jan.18. 2012          Version 1.0  6 • Pregnancy (known to be pregnant; to be confirmed before CCTA 
and/or randomization, if applicable)  
• Patient with eGFR 30- 59 ml/min who, in the judgment of  the patient’s 
physician, is likely to have significant unprotected left main stenosis  
• Enrolled in a competing trial that involves a non- approved cardiac drug 
or device 
• Inability to comply with the protocol  
• Exceeds the weight or size limit for CCTA or cardiac catheterization at 
the site  
Primary Endpoint  Time to first occurrence of cardiovascular death or nonfatal myocardial 
infarction.  
Secondary 
Endpoints  • Angina control per SAQ Angina Frequency Scale  
• Disease -specific quality of life per SAQ Quality of Life Scale  
• Composite of cardiovascular death, nonfatal myocardial infarction, or 
stroke 
• Composite of cardiovascular death, nonfatal myocardial infarction, 
resuscitated cardiac arrest, or hospi[INVESTIGATOR_587839]  
• All-cause death  
• Cardiovascular death  
• Nonfatal MI  
• Resuscitated cardiac arrest  
• Hospi[INVESTIGATOR_10929]  
• Hospi[INVESTIGATOR_19934] 
• Stroke 
• Composite of cardiovascular death, nonfatal myocardial infarction, 
stroke, resuscitated cardiac arrest, hospi[INVESTIGATOR_587840].  
• Health resource utilization, cost s, and cost -effectiveness  
Assessment 
Schedule Pre-eligibility screening, CCTA visit, randomization, 1 .5 month s, 3 months, 
6 months, 12 months, and every 6 months thereafter.  
Study Duration  Enrollment will occur over approximately 4  years with an expected 
minimum of 18 -24 months follow -up and an average of approximately 
  
 
Protocol Date: Jan.18. 2012          Version 1.0  7 4 years follow -up.  
Clinical Event 
Adjudication 
Committee  The following events will be adjudicated by a blinded Clinical Event 
Adjudication Committee: death, myocardial infarction, resuscitated cardiac arrest, hospi[INVESTIGATOR_10929], hospi[INVESTIGATOR_19934], 
stroke, and transient ischemic attac k. 
Data and Safety 
Monitoring Board  An independent Data and Safety Monitoring Board will advise the NHLBI 
and study leadership on safety aspects and overall progress of the study.  
Statistical 
Considerations  A sample size of approximately 8,000 randomized  participant s is expected 
to provide over 90% power to detect a 15% reduction in the primary 
composite event rate in participant s randomized to INV as compared with 
CON strateg y. 
 
  
 
   
 
   
 
 
   
 
  
 
Protocol Date: Jan.18. [ADDRESS_774069] OF ABBREVIATIONS AND DEFINITIONS  ...................................................................................... 11 
2. BACKGROUND AND RATIONALE  ........................................................................................................ 15 
3. HYPOTHESIS  ........................................................................................................................................ 18 
4. STUDY OBJEC TIVES  ............................................................................................................................. 19 
5. STUDY DESIGN  .................................................................................................................................... 20 
5.1 Study Flow  ........................................................................................................................ 20 
5.2 Study Population ............................................................................................................... 22 
5.3 Inclusion/Exclusion Criteria  ............................................................................................... 22 
5.3.1  Criteria Prior to Informed Consent  ....................................................................................................... 22 
5.3.2  Criteria After Enrollment (Informed Consent) and Prior to Randomization  ....................................... 23 
6. STUDY PROCEDURES  .......................................................................................................................... 24 
6.1 Qualifying Stress Imaging Study ......................................................................................... 24 
6.2 Informed Consent Process  .................................................................................................  24 
6.3 Interactive Voice Response System (IVRS) and Interactive Web Response System (IXRS)  ..... 25 
6.4 Core Lab Ischemia Verification ........................................................................................... 25 
6.5 Coronary Computed Tomography Angiography (CCTA)  ....................................................... 26 
7. MANAGEMENT STRATEGIES  .............................................................................................................. 28 
7.1 Conservative (CON) Strategy  .............................................................................................. 28 
7.2 Invasive (INV) Strategy  ...................................................................................................... 28 
7.3 Optimal Medical Therapy (OMT)  ........................................................................................ 28 
7.3.1  Management of Angina in CON Participants ........................................................................................ 29 
7.3.2  Management of Angina in INV Participants  ......................................................................................... 29 
7.4 Optimal Revascularization Therapy (ORT)  .......................................................................... [ADDRESS_774070] PCI vs. CABG  .............................................................................................................. 30 
7.4.2  Guidelines for Optimal Percutaneous Coronary Intervention  ............................................................. 30 
7.4.3  Guidelines for Optimal Surgical Revascularization  .............................................................................. 30 
7.5 Maximizing Adherence to CON Strategy  ............................................................................. 30 
7.6 Cath in Participants Randomized to CON Strategy  .............................................................. 31 
8. AUXILLIARY SCREENING LOG AND SURVEY  ....................................................................................... 33 
8.1 Screening Log  .................................................................................................................... 33 
8.2 Screening Survey  ............................................................................................................... 33 
9. Study Assessments  ............................................................................................................................. 35 
  
 
Protocol Date: Jan.18. [ADDRESS_774071] Blood Tests  ......................................................................................................... 35 
9.3 Endpoint Assessments  ....................................................................................................... 35 
9.4 Blood Biomarkers and Genomics Biorepository  .................................................................. 35 
9.5 Medication Adherence  ...................................................................................................... 36 
9.6 Lifestyle Assessment  ......................................................................................................... 36 
9.7 Quality of Life Assessment  .................................................................................................  36 
9.8 Economics Assessment  ...................................................................................................... 36 
10. SCHEDULE OF ASSESSMENTS  ......................................................................................................... 38 
11. ADJUDICATION OF CLINICAL EVENTS  ............................................................................................ 48 
12. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN  ............................................................. 49 
12.1 Sample Size Determination and Statistical Power  ............................................................... 49 
12.1.1  Considerations and Assumptions  ..................................................................................................... 49 
12.1.2  Summary of Power and Precision  .................................................................................................... 49 
12.2 Statistical Analysis Plan  ..................................................................................................... 51 
12.2.1  Analysis of the Primary Endpoint  ..................................................................................................... 51 
12.2.2  Analysis of the Secondary Endpoints  ............................................................................................... 51 
12.2.3  Contingency Plan For Insufficient Primary Endpoint Events  ........................................................... 52 
12.2.4  Quality of Life (QOL) Analysis  ........................................................................................................... [ADDRESS_774072] KEEPI[INVESTIGATOR_1645]  ...................................................................................... 56 
13.1 Electronic Data Capture (EDC) System  ................................................................................ 56 
13.2 Data Management and Quality  .......................................................................................... 56 
13.3 Data Confidentiality and Security  ....................................................................................... 56 
13.4 Training  ............................................................................................................................ 57 
13.5 Records Retention  ............................................................................................................. 57 
13.6 Management of Economic and Quality of Life (EQOL) Data  ................................................. [ADDRESS_774073]  ..................................................................................... 58 
14.2 Risks and Benefits  ............................................................................................................. 58 
14.3 Safety Monitoring Objectives and Rationale  ...................................................................... 59 
14.4 Adverse Events Reporting by [CONTACT_4718]  ......................................................................... 60 
14.5 Events to be Monitored  ..................................................................................................... 60 
  
 
Protocol Date: Jan.18. 2012          Version 1.0  10 15. ETHICAL CONSIDERATIONS  ............................................................................................................ 62 
15.1 Regulatory and Ethical Compliance  .................................................................................... 62 
15.2 Informed Consent Process  .................................................................................................  62 
15.3 Responsibilities of the Investigator and IRB/IEC/REB  .......................................................... 62 
15.4 Protocol Amendments  ....................................................................................................... 63 
15.5 Early Termination of the Study  .......................................................................................... 63 
16. STUDY ORGANIZATION  .................................................................................................................. 64 
17. DATA ACCESS AND SHARING  ......................................................................................................... 65 
18. PUBLICATIONS POLICY: OVERVIEW  ............................................................................................... [ADDRESS_774074]  .............................................................................................................................. 67 
 
  
 
Protocol Date: Jan.18. [ADDRESS_774075] aspartate aminotransferase  
ALT alanine aminotransferase  
BARI 2D  By[CONTACT_587865] 2 Diabetes trial  
CABG  coronary artery by[CONTACT_587866]-MB creatinine kinase -MB 
CL Core laboratory  
CMR  cardiac magnetic resonance  
CON  Conservative management strategy (initial management with OMT alone, with 
cath and revascularization reserved for refractory symptoms or acute ischemic 
events)  
COURAGE  Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation 
trial 
CV cardiovascular  
DASI  Duke Activity Status Index  
DNA  deoxyribonucleic acid  
  
 
Protocol Date: Jan.18. [ADDRESS_774076]  
ICC Ischemia Imaging Coordinating Center  
ICH International Conference on Harmonization  
IEC institutional ethics committee  
INV invasive management strategy (cath with intent to perform optimal 
revascularization plus optimal medical therapy)  
IRB Institutional Review Board  
ISCHEMIA  International Study of Comparative Health Effectiveness with Medical and 
Invasive Approaches trial  
  
 
Protocol Date: Jan.18. [ADDRESS_774077] – Revised  
LVEF  left ventricular ejection fraction  
MI myocardial infarction  
MOE  margin of error  
MOO  Manual of Operations  
MPI [INVESTIGATOR_587841], Lung, and Blood Institute  
NIH National Institutes of Health  
NINDS  National Institute of Neurological Disorders and Stroke  
NYHA  [LOCATION_001] Heart Association  
OMT  optimal medical therapy  
ORT  optimal revascularization therapy  
PACE  Patient -centered Assessment and Counseling for Exercise and nutrition  
PCI percutaneous coronary intervention  
PET positron emission tomography  
PHI protected health information  
PHQ -[ADDRESS_774078]  
  
 
Protocol Date: Jan.18. [ADDRESS_774079]  single photon emission computed tomography  
WHF  World Heart Federation  
 
  
 
Protocol Date: Jan.18. 2012          Version 1.0  15 2. BACKGROUND AND RATIONALE  
Coronary artery disease (CAD) is the leading cause of death and disability worldwide and 
affects 17.6 million Americans, resulting in about 450,000 deaths in the [LOCATION_002] annually.1 
Globally, 7.2 million deaths are caused by [CONTACT_587867].2 An invasive approach to the 
evaluation and treatment of CAD is common, yet evidence that this approach to management 
favorably influences long- term clinical outcomes in patients with stable ischemic heart disease 
(SIHD) is outdated. In randomized clinical trials conducted in the 1970s, surgical revascularization (coronary artery by[CONTACT_9292] [CABG]) improved survival compared to medical 
therapy in SIHD patients.
3-[ADDRESS_774080] importantly, effective medical therapy proven in more recent trials to reduce  
clinical events was used minimally if at all. These therapi[INVESTIGATOR_587842], beta -blockers, 
statins, angiotensin- converting -enzyme (ACE) inhibitors, and lifestyle interventions.7-17 High-
dose statins, in particular, are disease and prognosis modifying agents. Moreover, in aggregate, 
these therapi[INVESTIGATOR_587843] ~50% relative r eduction in risk of clinical events.9, 18-
[ADDRESS_774081], speculative.  
In the contemporary era, revascularization in addition to medical therapy vs. medical therapy 
alone has been studied in several patient populations. The Surgical Treatment for Ischemic 
Heart Failure (STICH) trial assessed all -cause mortality for CABG vs. medical therapy alone in a 
heart failure cohort  at high risk of death: those with severe HF, an ejection fraction ≤35%, and 
coronary artery disease. These patients are excluded from the ISCHEMIA trial. STICH reported 
no significant difference in all -cause mortality (the primary end point) between the t wo treatment 
strategies (P = 0.12); CABG reduced the composite of CV death and hospi[INVESTIGATOR_059].[ADDRESS_774082] 
from CABG, as compared with medical therapy alone.22  
The Clinical Outcomes Utilizing Revascularization and A ggressive Drug Evaluation 
(COURAGE)23 and the By[CONTACT_587865] 2 Diabetes 
(BARI  2D)24 trials demonstrated that in patients with SIHD, predominantly without severe LV 
dysfunction, a management strategy of revascularization plus optimal medical therapy (OMT) did not reduce the risk of death or MI as compared with OMT alone. Importantly, both of these 
trials randomized patients after cardiac catheterization (cath). Cath is an invasive diagnostic test 
that typi[INVESTIGATOR_587844] a therapeutic cascade involving revascularization.
25 This phenomenon is 
attributed, in part, to the common attitude among patients and physicians that visualized 
stenoses need to be “fixed” and that a revasculariz ation procedure will prolong their lives and/or 
prevent MI, not just relieve angina.26-28 Consequently, the decision to proceed with 
revasc ularization often hinges more on anatomic feasibility than on evidence that 
revascularization is clinically beneficial.26, 28 The inherent assumption of this approach is that 
coronary revascularization of flow -limiting stenoses will prevent or reduce clinical events. This 
assumption is not w arranted, based on the results of modern randomized trials.   
  
 
Protocol Date: Jan.18. [ADDRESS_774083] moderate ischemia on myocardial perfusion imaging (MPI),
35-37 but this concept has never been fully tested in a prospective, randomized clinical trial. 
Within a small (n=314) nuclear substudy of patients who had baseline and follow -up stress 
perfusion scans at 6- [ADDRESS_774084] 
moderate ischemia at baseline, as measured by [CONTACT_79086] [INVESTIGATOR_2993] a core laboratory. Among these 105 patients, there  was a significantly greater reduction in ischemia associated with PCI and OMT 
than OMT alone on follow -up MPI.
38 For PCI and OMT groups combined, the ra te of death or MI 
over 3.6 years was 16% for those who experienced ischemia reduction compared with 34% for 
those without significant ischemia reduction on follow -up MPI. These results support the 
hypothesis that the benefit of an invasive strategy in SIHD  patients is most likely to be observed 
in patients with at least moderate ischemia. In contrast, a newer , unpublished COURAGE 
analysis of outcomes by [CONTACT_587868] [ADDRESS_774085] to the ascertainment of a follow -up study, showed no 
reduction in death/MI (PCI and OMT vs. OMT 24% vs. 21%, respectively, hazard ratio [HR] 1.19, 95% confidence interval [CI] 0.65 -2.18) . The same lack of benefit for PCI was 
demonstrated for a larger cohort of [ADDRESS_774086] that only 35 to 65% of patients 
with moderate or severe ischemia on MPI [INVESTIGATOR_587845], reflecting equipoise in the 
community.
39-[ADDRESS_774087] been performed before the COURAGE and BARI 2D results were available. Moderate or severe 
ischemia is a marker for increased risk for death, but no well -designed clinical t rial of patients 
with this degree of ischemia has studied whether an invasive strategy improves clinical 
  
 
Protocol Date: Jan.18. [ADDRESS_774088] profound implications for 
guidelines, health policy, and clinical practice.  
 
  
 
Protocol Date: Jan.18. 2012          Version 1.0  18 3. HYPOTHESIS  
An invasive (INV) approach of routine early cardiac catheter ization with intent for optimal 
revascularization in addition to OMT will reduce the incidence of major adverse cardiovascular 
events over an average of approximately [ADDRESS_774089] 
moderate ischemia as compared with an init ial conservative (CON) approach of OMT alone, 
with catheterization reserved for refractory angina symptoms, acute coronary syndrome, acute 
ischemic heart failure, or resuscitated cardiac arrest.  
  
 
Protocol Date: Jan.18. [ADDRESS_774090].  
SECONDARY AIMS 
The secondary aims are to compare the following clinical and economic outcomes in 
participant s randomized to INV or CON strategies : 
• Angina control, as assessed by [CONTACT_345500] (SAQ) Angina Frequency scale 
• Disease -specific quality of life, as assessed by [CONTACT_587869]   
• Composite of cardiovascular death, nonfatal myocardial infarction, or stroke 
• Composite of cardiovascular death, nonfatal myocardial infarction, resuscitated cardiac arrest, or hospi[INVESTIGATOR_587846]  
• All-cause death  
• Cardiovascular death  
• Nonfatal MI  
• Resuscitated cardiac arrest  
• Hospi[INVESTIGATOR_10929]  
• Hospi[INVESTIGATOR_19934] 
• Stroke 
• Composite of cardiovascular death, nonfatal myocardial infarction, stroke, resuscitated 
cardiac arrest, or hospi[INVESTIGATOR_587846].  
• Health resource utilization, costs, and cost -effectiveness  
 
 
 
  
 
Protocol Date: Jan.18. [ADDRESS_774091] 
moderate ischemia on stress imaging will be randomized in a 1:[ADDRESS_774092] moderate ischemia on stress imaging ( see section 
6.1) will be identified and screened for clinical inclusion/exclusion criteria ( see section 5.3 ). 
Patients who meet clinical and ischemia (site -interpreted) eligibility criteria and are interested in 
participating in the trial will be enrolled by [CONTACT_587870] a study 
number via the interactive voice response system (IV RS) or interactive web response system 
(IXRS) ( see section 6.3 ). Stress testing images will be transferred to the imaging core lab 
electronically for all enrolled participant s (see Figure 1) .  All participant s with eGFR  >60 ml/min 
will undergo a blinded CCTA. CCTA images will also be transferred electronically to the CCTA core lab for interpretation.  CCTAs will only be interpreted by [CONTACT_587871]. The participant , participant ’s physician, and site will not have access to the results of the 
CCTA unless the core lab determines the results reveal: 1) unprotected left main coronary 
artery stenosis (defined as ≥50% and not previously by[CONTACT_92842]); 2) no obstructive lesions 
(≥50%) in any major coronary artery; or 3) incidental findings of clinical importance, such as an 
aortic aneurysm or suspected neoplasm. In the event of any of these three findings, the 
participant will not be eligible to continue in the study, and these results will be communicated to 
the site. The images will then be made available to the site for clinical use. All participant s 
meeting CCTA eligibility criteria (see section 6.5) will then be randomized to the INV or CON strategy v ia the IVRS/IXRS system.  
 Participant s with eGFR 30- 59 ml/min will not undergo a CCTA due to the increased risk of 
developi[INVESTIGATOR_587847] -induced nephropathy .  Participant s with eGFR 30- 59 ml/min who , according 
to the participant ’s physician,  are unlikely to have significant unprotected left main stenosis , will 
proceed directly  to randomization. (Patients with eGFR <30 ml/min are not eligible for the trial.)  
Patients with eGFR 30- 59 ml/min will not be enrolled into the study if the patient’s physician 
suspects significant left main stenosis on the basis of stress hemodynamic, ECG, and imaging 
results.  
Participants determined to be eligible for randomization should be randomized within a target of 
15 days of consent, and participant s randomized to INV strategy should undergo catheterization 
within a target of 30 days after randomization, with optimal revascularization therapy (ORT) 
soon thereafter as appropriate. Participant s will be enrolled over approximately 4 years . 
Randomized participant s will be followed for an average of approximately 4 years .  The 
minimum follow -up period for randomized participant s will be approximately 18- 24 months 
following randomization of the final participant. A schedule of assessments is provided in 
section 10 .
  
 
Protocol Date: Jan.18. 2012          Version 1.0  21  
Figure 1 Study Flow  
 
 

 
Protocol Date: Jan.18. [ADDRESS_774093] moderate ischemia on stress imaging.  SIHD is synonymous with 
stable coronary artery disease, and refers to patients  with coronary artery disease who are 
clinically stable (i.e., who are not in an un stable phase such as an acute coronary syndrome).  
 
5.3 Inclusion/Exclusion Criteria  
 
Screening for i nclusion/exclusion criteria will be conducted in two phases. First, clinical and 
ischemia criteria at the local site will be used to obtain informed consent; and second, after 
informed consent is obtained but before randomization, criteria for  CCTA eligibility will be 
assessed . Stress imaging core labs will work with sites to ensure randomization of participants 
with at least moderate ischemia.  
5.3.1  Criteria Prior to Informed Consent  
Patients will be screened for the following inclusion and exclusion criteria:  
Inclusion (pre informed consent)  
1. At least moderate ischemia on qualifying stress imaging test (See Table 1 ) 
2. Participant  is willing to give informed consent  
3. Age ≥ 21 years  
Exclusion (pre informed consent)  
1. LVEF <35%  
2. History of unprotected left main stenosis ≥50% on prior coronary computed tomography 
angiography (CCTA) or prior cardiac catheterization (if available)  
3. Finding of “no obstructive CAD” (<50% stenosis in all major epi[INVESTIGATOR_587848]) on prior 
CCTA or prior catheterization, performed within 12 months  
4. Prior known coronary anatomy unsuitable for either PCI or CABG  
5. Unacceptable level of angina despi[INVESTIGATOR_133349]  
6. Very dissatisfied with medical management of angina  
7. History  of noncompliance with medical therapy  
8. Acute coronary syndrome within the previous 2 months  
9. PCI or CABG within the previous 12 months  
10. Stroke within the previous 6 months or intracranial hemorrhage at any time  
11. History of ventricular tachycardia requiring t herapy for termination, or symptomatic 
sustained ventricular tachycardia  
 
Protocol Date: Jan.18. 2012          Version 1.0  23 12. NYHA class III -IV heart failure at entry or hospi[INVESTIGATOR_587849] 6 months  
13. Non-ischemic dilated or hypertrophic cardiomyopathy  
14. End stage renal disease on dialysis or estimated glomerular filtration rate (eGFR) <30 
ml/min  
15. Severe valvular disease or valvular disease likely to require surgery within [ADDRESS_774094]  
17. Planned major surgery necessitating interruption of dual antiplatelet therapy  
18. Life expectancy less than 5 years due to non -cardiovascular comorbidity  
19. Pregnancy (known to be pregnant; to be confirmed pre -CCTA a nd/or randomization, if 
applicable)  
20. Patient  with eGFR 30- 59 ml/min who, in the judgment of the patient’s  physician,  is  likely 
to have significant unprotected left main stenosis  
21. Enrolled in a competing trial that involves a non- approved cardiac drug or device  
22. Inability to comply with the protocol  
23. Exceeds the weight or size limit for CCTA or cardiac catheterization at the site 
 
5.3.2  Criteria After Enrollment (Informed Consent) and Prior to Randomization  
Participants  who provide informed consent and are clinically eligible will be  registered via the 
IVRS/IXRS system.  They  are considered enrolled and will undergo measurement of ischemia by 
[CONTACT_587872] a blinded CCTA ( if eGFR > 60 ml/min). Participant s me eting the 
following exclusion criteria will not be randomized.  
Exclusion (after informed consent and before randomization)  
1. Pregnant (negative pregnancy test before CCTA required for premenopausal females)  
2. Left main stenosis ≥50% (unprotected) on CCTA  
3. Finding of “no obstructive coronary artery disease” (<50% stenosis) in all major 
epi[INVESTIGATOR_587850]  
4. Incidental finding s on CCTA of clinical importance (e.g., lung mass suspi[INVESTIGATOR_146246] ; see MOO for details ) 
5. Interval development of a clinical exclusion criterion or a primary or secondary  endpoint 
event.
 
Protocol Date: Jan.18. [ADDRESS_774095] modalities will be allowed for inclusion using exercise or 
pharmacologic stress:  
• Nuclear perfusion imaging (single photon emission computed tomography [SPECT] or 
positron emission tomography [PET])  
• Echocardiography (Echo)  
• Cardiac magnetic resonance (CMR)  
Non-imaging stress tests (ECG only) will not  be permitted to determine eligibility. The criteria for at 
least moderate ischemia with each imaging modality are listed in Table [ADDRESS_774096] been on or off 
medications on the day of the stress imaging study documenting eligibility, consistent with 
customary clinical practice.36, 37 A 24-hour, 7 -day helpline will be available to sites for assistance with 
ascertainment of eligibility, enrollment, and adherence to protocol.  
 
Table 1: Criteria for at least Moderate Ischemia by [CONTACT_587873]  ≥10% myocardium  ischemic  
Echo  ≥3/16 segments with stress -induced severe hypokinesis or 
akinesis  
CMR  perfusion: ≥12% myocardium  ischemic  
and/or wall motion: ≥3/[ADDRESS_774097]=single photon emission computed tomography, PET=positron emission tomography; Echo= echocardiography; 
CMR=cardiac magnetic resonance  
 
6.2 Informed Consent Process  
The study will be reviewed with the prospective study participant  by [CONTACT_15009]/her 
designee. The prospective study p articipant  will be given adequate time to read the written consent 
form.  The investigator  or his/her designee will be available to answer questions about the study 
including procedures, risks, and alternatives. The informed consent form will be signed and dated by 
[CONTACT_587874].  
 
Protocol Date: Jan.18. 2012          Version 1.0  25 In addition, prospective study p articipants  will be requested to consent to a biorepository sample, 
and to allow use of the biorepository sample for genetic testing (DNA).  P rospective study 
participant s will be informed that declining participation in the Biomarker or Genetic Testing portion 
of the study does not preclude their participation in the main study.  A copy of the signed consent 
form will be given to the participant  and the original(s) will be kept securely with each p articipant ’s 
research records.   
Specific consent will be obtained bef ore any protocol -mandated procedure that requires consent 
(including CCTA) is performed. The consent will allow for protected health information (PHI) to be 
transferred to the Clinical Coordinating Center (CCC ) and/or the Regional Research Organization 
that serves as the Coordinating Center in the country/region unless prohibited by [CONTACT_19124]. This 
will make it possible for another site within that country or the CCC to follow participant s if a site 
closes down or cannot continue follow -up for any reason , and to look up vital status . Privacy 
regulations in all countries will be followed, (e.g., Health Insurance Portability and Accountability Act [HIPAA] in the US; Personal Information Protection and Electronic Documents Act [PI[INVESTIGATOR_15654]] in 
Canada; European Uni on Directive on Data Privacy [EU Directive]). For North American participants 
only, PHI will also be sent to the EQOLCC . 
6.3 Interactive Voice Response System (IVRS) and Interactive Web Response 
System (IXRS)  
Enrollment and randomization will be accomplished by [CONTACT_587875]. When a 
participant  meeting site -determined clinical and stress imaging criteria has provided informed 
consent, the study coordinator or investigator at the site will call the IVRS  or log on to the  IXRS  to 
receive a partic ipant  identification number.  At this point the pa rticipant  is registered as enrolled.   
Several language options will be provided for international sites using IVRS/IXRS. To eliminate any 
manual transcription errors , IVRS/IXRS will be programmed to electr onically transfer the participant  
data and study identification number to create the participant ’s case book within the electronic data 
capture (EDC) system.  
In order to randomize the participant , the study coordinator or investigator will call IVRS or lo g in to 
IXRS a second time. Subjects meeting all clinical, site, and core lab inclusion/exclusion criteria will 
then be randomized to either the INV or CON strategy and will be registered as randomized. This 
information will be transmitted to the participa nt’s electronic case book within the EDC system.  
Detailed information on enrollment and randomization will be provided in the MOO  and in specific 
IVRS/IXRS  materials . 
6.[ADDRESS_774098] moderate ischemia, s tress imaging core labs will certify that sites 
 
Protocol Date: Jan.18. 2012          Version 1.0  26 can continue to  advance participants to the next step, CCTA (or randomization, if the eGFR is 30-
59ml/min ). (See MOO .) 
6.5 Coronary Computed Tomography Angiography (CCTA)  
Coronary computed tomography angiography (CCTA) will be performed in all participant s with eGFR 
≥60ml/min to identify and exclude participant s with obstructive left main stenosis (defined as ≥50% 
unprotected stenosis) and participant s with out obstructive coronary stenoses ( with <50% stenosis in 
all epi[INVESTIGATOR_494890]). Study staff will not view the CCTA; only the CCTA core l aboratory 
will interpret results and sites will be blinded to the results of the scan. The scan and interpretation  
will not be stored i n the local clinical imaging system. Participant s with eGFR 30- 59 ml/min will not 
undergo a CCTA due to the risk of devel opi[INVESTIGATOR_587847] -induced nephropathy. In this subpopulation, 
participant s can be randomized if the treating physician does not suspect significant unprotected left 
main stenosis based on the results of the stress test, including the imaging portion. However,  if a 
significant left main stenosis is suspected, these participant s will not be enrolled into the study.   
Radiation reduction techniques will be used. We will prescribe standardized patient -specific image 
acquisition protocols that permit high quality CCTA with low dose radiation. Radiation reduction 
methods will include ECG dose modulation, weight -based tube voltage, minimization of Z- axis 
coverage, limiting the field of view, and automatic exposure control. Importantly, all of these dose 
reduction tec hniques are additive, can be programmed into a single default protocol, and are 
available in all ≥64- detector row CT scanners.  The investigative group has evaluated the efficacy of 
combined dose reduction techniques and found a >90% reduction in biological  radiation dose 
(1-2 mSv) without compromise of image quality or diagnostic accuracy.48-52 Each site will be 
provided with a concise , easy -to-read manual and an instructional video, prepared for this trial, on 
how to obtain high quality CCTA images with low radiation dose. For newer scanners, we will 
employ further dose reduction algorithms including prospective ECG triggering, minimization of 
padding, and iterative reconstruction techniques.  
The CCTA core laboratory will interpret the images and sites will be notified if the participant  is or is 
not eligible because of significant unprotected left main coronary artery stenosis or the absence of obstructive stenoses. Further definition of the anatomy will not be disclosed to the participant , 
treating physicians, or the site unless the participant  is not eligible for randomization. Participant s 
with incidental findings of clinical importance, such as aortic aneurysm or suspected neoplasm ; see 
MOO for details) , will not be randomized and the interpretation of the CT, including coronary 
anatomy, will be made available to the treating physicians. In addition, there may be findings on CT of potential clinical significance that will not exclude patients from the study, such as small lung  
nodules.  In such cases, treating physicians will be given access to and will be encouraged to review 
the CT images locally.  
If a trial -consented participant  is not randomized after CCTA, despi[INVESTIGATOR_587851], maintenance of investigator blinding will be investigated.  
Participant s meeting the clinical, ischemia, and  CCTA eligibility ( or physician judgment  for 
participant s with eGFR 30 -59 ml/min) will be randomized to the INV or CON strategy via the 
 
Protocol Date: Jan.18. 2012          Version 1.0  27 IVRS/IXRS system. The targeted time to randomize a participant  after consent is obtained is 15 
days  (see Figure 1) . 
 
Protocol Date: Jan.18. 2012          Version 1.0  28 7. MANAGEMENT STRATEGIES 
Table 3.   Components of CON and INV management strategies  
 
CON ( Section 7.1 )  
INV (Section  7.2) 
• Optimal medical therapy (OMT; includes 
angina management) ( Section 7.3 ) 
• Provisional cardiac catheterization ( Section 
7.6) • Optimal medical therapy (OMT; includes 
angina management) ( Section 7.3 ) 
• Cardiac catheterization  
• Optimal revascularization therapy (ORT)  
(Section 7.4 ) 
 
7.1 Conservative (CON) Strategy  
In participant s randomized to the CON strategy, initial management with OMT alone will be 
employed (described below). A fundamental principle of the CON strategy is to restrict cath to 
participant s who fail OMT, i.e. , those who experience an acute coronary syndrome, acute ischemic 
heart failure or resuscitated cardiac arrest or who have angina that is refractory to maximal medical 
therapy. In such participant s who require cath during follow -up, revascularization should be 
performed using the principles of optimal revascularization therapy as outlined below.  
7.2 Invasive (INV) Strategy  
In participant s randomized to INV strategy, initial management with cath will be performed, with 
subsequent revascularization, as appropriate, based upon coronary anatomy and other clinical 
considerations. The principles of optimal revascularization therapy will be followed ( described 
below). In addition, all INV participant s will receive OMT as outlined below.  
7.3 Optimal Medical Therapy (OMT)  
OMT will consist of intensive, comprehensive secondary prevention with lifestyle and pharmacologic 
intervention applied equally to both t reatment groups using individualized treatment regimens based 
on treat -to-target algorithms under supervision by [CONTACT_7880] [INVESTIGATOR_587852] ’s 
primary care physician and/or cardiologist. The research team in collaboration with the participant ’s 
treating physicians will implement changes in medical therapy in keepi[INVESTIGATOR_587853]. The research team will obtain results of routine laboratory tests that reflect 
secondary prevention targets performed by [CONTACT_2299] ’s physician and provide the results of any 
tests obtained by [CONTACT_587876] ’s physician. Behavioral interventions will focus on 
smoking cessation, nutrition, physical activity, weight control, and medication adherence. 
Pharmacologic interventi ons will include anti -atherothrombotic and anti -ischemic medications. The 
 
Protocol Date: Jan.18. 2012          Version 1.0  29 minimum goals of OMT will be those recommended for SIHD patient s by [CONTACT_30104]/international 
organizations (e.g., the National Cholesterol Education Program, American College of Cardiology, 
American Heart Association, European Society of Cardiology, and World Health Organization). 
Details of this strategy are provided in the MOO and will be updated, as needed, over the course of 
the trial.  
7.3.1  Management of Angina in CON Participant s 
Medica l management of angina in CON participant s will be intensified according to the ISCHEMIA 
angina treatment algorithm (see MOO). The goal for all CON participant s is to control angina such 
that participant s report a good angina- related quality of life. If the level of angina is unacceptable to 
the participant  despi[INVESTIGATOR_133349], then cath and possible revascularization is 
recommended, consistent with good medical care.  
7.3.2  Management of Angina in INV Participant s 
Participant s randomized to the INV strategy who experience angina following revascularization may 
be treated medically, as per the ISCHEMIA angina treatment algorithm (see MOO). The goal for all INV participant s is to control angina such that participant s report a good a ngina -related quality of life. 
Unlike the approach to CON participant s with angina, repeat cath and revascularization may be 
performed without first maximizing medical therapy in INV participant s. 
7.4 Optimal Revascularization Therapy (ORT)  
Optimal revasculari zation therapy will be performed based on findings from the diagnostic 
catheterization and relevant clinical information. While the selection of PCI vs. CABG (or medical 
therapy only in cases of normal coronary arteries, diffuse small vessel disease, etc.)  will be left to 
the discretion of the treating team per local standards and expertise, several general principles 
should be followed:  
• The revascularization modality selected should have the highest likelihood to safely and 
effectively relieve significant ischemia in all viable myocardial territories of at least moderate 
size.  
• Decisions regarding viability testing and revascularization decisions based on such testing 
should be based on routine clinical practice.  
• Revascularization should be performed with a goal of relieving all areas of significant 
ischemia, i.e., ischemia that would be detected by [CONTACT_105]- invasive imaging.  
• Prior to selection of the revascularization modality, ischemic territories should be identified 
based on the results of noninvasive tests, angiography and, in selected cases, FFR (as outlined in the MOO).   
Details of ORT are provided in the MOO and will be updated, as needed, over the course of the trial.  
 
 
 
Protocol Date: Jan.18. [ADDRESS_774099] PCI vs. CABG  
In general, the decision between PCI and CABG will be determined according to local hospi[INVESTIGATOR_587854]. Guidelines from professional societies and appropriateness criteria should be incorporated into the decision process. It is desirable for the study Heart Team (interventional 
cardiologist and cardiac surgeon) to discuss each case after diagnostic angiogram to reach a 
consensus as to the best revascularization technique.  
It is recognized, however, that in some cases of non- complex coronary artery disease the 
performance of “ad hoc” PCI after diagnostic angiography may be preferred by [CONTACT_3445] s and 
physicians. Whenever possible, the Heart Team should record an opi[INVESTIGATOR_587855] h participant  
regarding the best mode of revascularization, reaching consensus where possible and recording disagreement if not possible.   
Details are provided in the MOO.  
7.4.[ADDRESS_774100] to the progressive nature of atherosclerotic heart disease. This goes well beyond the 
intraoperative techni cal aspects of surgical revascularization.  
 
The principles for optimal CABG include:  
• Accurate assessment and evaluation of potential CABG participant s 
• Complete revascularization (anatomic and physiologic criteria)  
• Optimize intraoperative management, including myocardial protection  
• Minimize associated organ and system injury  
• Maximize opportunity for long- term graft patency  
• Optimize secondary prevention of atherosclerotic heart disease following CABG.  
 
Details of this are provided in the MOO.  
 
7.5 Maximizing Adherence to CON Strategy  
Adherence to the CON strategy means that all CON participant s receive OMT and that none 
undergo cath or revascularization unless they 1) have an acute coronary syndrome, resuscitated 
cardiac arrest, or acute ischemic heart failure  or 2) have unacceptable angina refractory to maximal 
medical therapy (see MOO for definition and recommended management of refractory angina). Cath 
 
Protocol Date: Jan.18. [ADDRESS_774101].  
 
7.6 Cath in Participant s Randomized to CON Strategy  
Cath and/or revascularization for an acute coronary syndrome, resuscitated cardiac arrest, or acute ischemic heart failure is consistent with the CON strategy. Similarly, cath for refractory symptoms (according to the trial definition) is also consistent with CON strategy. Figure 2
 describes cath in 
participant s randomized to CON and the definitions of protocol adherence and non -adherence as it 
relates to this. Once the decision has been made that the performance of cath in a CON participant  
is consistent with the CON strategy, the same principles described for optimal revascularization ( 7.4) 
apply.  
 
 
  
 
   
 
   
 
Protocol Date: Jan.18. 2012          Version 1.0  32 Figure 2   Cath in Participant s Randomized to CON Strategy  
 

 
Protocol Date: Jan.18. [ADDRESS_774102] undergone testing at the site’s 
designated primary stress imaging laboratory. Patient characteristics (age [recorded for patients <90 
years of age, recorded as 90 if > 90 years of age], sex, and, if excluded, reason(s) for exclusion will 
be recorded).  
The screening log will be sent to the CCC on a regular basis, where it will help identify the major 
reasons why patients are not enrolled, thus allowing CCC staff to develop corrective action plans for 
sites that are not meeting target enrollment. Depending on the site’s enrollment rate over time, the 
CCC may decide that a given site no longer needs to submit its screening log, although the site 
should continue to maintain the log through the end of enrollment. In the event of poor enrollment, sites may be asked to provide comparable information about patients referred to cath without prior 
stress imaging.  
 
8.[ADDRESS_774103] moderate 
ischemia who are screened but not enrolled by [CONTACT_3476]. The goal of this effort will be to describe the characteristics of patients who are screened but not enrolled and to document the 
major reasons for exclusion. This screening survey  will include the site’s primary stress imaging 
laboratory and any other screening and referral sources. Data will be entered via a web- based EDC 
system which will not include patient identifiers and will be separate from the main trial EDC system. 
For analysis, we will compare baseline characteristics and treatment plan of patients who were 
screened and met inclusion criteria but were not randomized with those who were randomized. This information will provide insight into any potential bias in trial enrol lment. Examples of data elements 
to be collected, when available, include:  
• Age (excluding any age ≥90)  
• Sex 
• Race/ethnicity  
• LVEF  
• Results of the stress imaging test (ischemia severity and location)  
• Basic medical history from stress imaging report (if availabl e) 
• Presence or absence of LM stenosis > 50% on previous CCTA or cardiac catheterization 
• History of ACS within the last 2  months  
• History of PCI or CABG within the last 12  months  
• History of stroke within the last 6  months or intracranial hemorrhage at any tim e 
• End stage renal disease  or  eGFR 15- 29 mL/min 
 
Protocol Date: Jan.18. 2012          Version 1.0  34 • History of NYHA III/IV heart failure or admission to hospi[INVESTIGATOR_587856] 6  months  
• Planned non cardiac surgery within the next 12 months  
• Severity of angina symptoms  
• Current anti -angina medications  
• Willingness  to take medications  
• Plan for treatment (e .g., cardiac catheterization, mode of revascularization if applicable)  
• Actual treatment received (e .g., cardiac catheterization, mode of revascularization if 
applicable)  
• Reason for not participating in the trial  
 
Only de-identified health information will be recorded.  An informed consent waiver will be obtained 
where applicable. There will be no follow -up of these screening survey patients.  
 
 
Protocol Date: Jan.18. [ADDRESS_774104] practice the following tests 
will typi[INVESTIGATOR_587857] ’s treating physician: complete blood count, electrolytes, 
creatinine, glucose, liver transaminases, lipid profile, and HbA1c. If HbA1c results are available for nondiabetic s they will be recorded. If these test results are not available within specified time 
windows around the randomization visit (see MOO), then they will be obtained (HbA1c required for diabetics only but recommended for all participant s). An attempt will be  made to coordinate 
participant  follow -up visits so that they occur close in time to routine follow -up visits with their 
physicians when routine blood tests are performed. At follow -up visits, if lipid tests (and HbA1c at 
annual visits for diabetics) are not available within specified time windows they will be obtained by 
[CONTACT_587877] s will be referred to their treating physicians for the tests.  
9.[ADDRESS_774105] 
study visit. See MOO for detailed instructions on collection of source documents.  
9.4 Blood Biomarkers and Genomics Biorepository  
Randomized participant s will be invited to participate in the biorepository protocol, unless precluded 
by [CONTACT_427]. Participant s who give informed consent will be asked to allow storage of 
samples of their blood in two biorepository protocols, one for biomarkers and one for genetic testing. 
Participant s who decline participation in one or both of the biorepository protocols are still eligible to 
participate in the main trial. The biorepositories will serve as resources for future analyses. Although no specific scientific proposals are put forth in the present protocol, we anticipate a wealth of 
opportunities for ancillary studies and sharing of resources with other investigators. Participant s will 
be asked to separately consent for use of their blood samples for the biomarker biorepository and 
the genetic  (DNA) biorepository . If a site is unable to process  blood samples they may still 
participate in the genetic biorepository; in this case saliva samples may be collected from 
participants.  
Blood will be drawn for the biorepository at the time of randomization, and may be drawn after 
3 months of follow -up. At the time of randomization, up to a maximum of 49 mL of whole blood will 
be collected, which will be processed and stored as serum, plasma, RNA and, where allowable, 
DNA. At the 3  month follow -up visit, up to 49 mL of blood may be drawn.   
 
Protocol Date: Jan.18. [ADDRESS_774106] the identity of the blood sample donor by [INVESTIGATOR_5328]- identifying the 
biospecimen samples at the enrollment site. The link between the pa rticipant's name [CONTACT_587925] b iorepository, or any 
investigative personnel requesting samples. Strict confidentiality and maintenance of the chain of 
custody will be observed in the collection and storage of biospecimens. Complete details of the 
biorepository protocol are provided in the MOO.  
9.5 Medication Adherence  
To assess medication adherence, a 4 -item modified Morisky adherence survey (Likert scale 
responses to 4 questions)53-56 will be completed at the randomization visi t, 6 month visit, and all 
subsequent visits.  
9.6 Lifestyle Assessment  
 
To assess each participant ’s readiness to change health- related behaviors, study coordinators will 
use questionnaires developed by [CONTACT_33230] -centered Assessment and Counseling for Exerci se and 
nutrition (PACE) program. Responses to these brief surveys will be used to tailor counseling for 
lifestyle change. These assessments will occur at randomization, 3 months, 12 months, annually, 
and at the closeout visit.  
 
9.7 Quality of Life Assessment  
 
To quantify the full spectrum of patient -reported quality of life outcomes in ISCHEMIA, a battery of 
validated instruments will be used. Angina- related quality of life will be measured by [CONTACT_587878] (SAQ); dyspnea symptoms from the R ose Dyspnea scale; physical function 
by [CONTACT_90050]- specific Duke Activity Status Index (DASI) and angina- specific SAQ physical 
limitations sub -scale; a Rand general health rating; psychological well -being and depression 
screening symptoms by [CONTACT_117671] (PSS) and Patient Health Questionnaire- 8 
(PHQ -8); a measure of optimism about the future from the Life Orientation Test -Revised (LOT -R); 
the EQ -5D as a measure of overall, generic health status; and demographic items ( e.g., marital 
status, ed ucation, perceived income).  We will use these data to analyze the health status of 
participant s in both groups over time to quantify both the magnitude and trajectory of health status 
recovery as a function of randomized management strategy.  
 
9.[ADDRESS_774107] and entered into the main 
study EDC database. These data, in conjunction with billing data (collected for the US study participants only by [CONTACT_587879] a database separate from the 
main EDC study database), will be used to estimate and compare medical care costs from the 
perspective of the US healthcare system for both management strategy groups. They will also be 
used, along with the clinical endpoints and quality of life data, to calculate the net increm ental cost 
 
Protocol Date: Jan.18. [ADDRESS_774108] -effectiveness ratio. Details are provided in the MOO.  
 
Protocol Date: Jan.18. 2012          Version 1.0  38 10. SCHEDULE OF ASSESSMENTS  
Overview of Visits 
All participant s will und ergo eligibility screening, informed consent, CCTA ( for all  participant s with 
eGFR >60 ml/min) and randomization procedures.  
Follow -up in randomized participant s will occur at [ADDRESS_774109] year and ever y 6 months thereafter, with clinic visits, phone follow -up, and other 
testing as described below (See Table 4  for complete assessment schedule). The schedule of 
assessments ( Table 4 ) specifies  the preferred method of contact [CONTACT_587880]. Six -month visits may 
be via telephone or email, depending on participant  stability, risk factor control, and the participant ’s 
distance from the clinic (“geography”) ( see Table 4 ). In the event that a scheduled clinic visit is not 
possible, to ensure participant  follow -up other forms of contact [CONTACT_587881], such as telephone, 
email, communication from a personal physician, other allied health professional, or family member, 
or review  of electronic health record or public records. After the first year, participant s will be 
followed every [ADDRESS_774110] been completed , unless 
prohibited by [CONTACT_427] . At these long- term follow -up contacts, information on current health 
and medications, and interval hospi[INVESTIGATOR_60614].  
Dependent on additional funding, telephone, in- person and/or email follow up may occur for 
participant s who are enrolled and subsequently excluded from randomization due to CCTA findings 
of no nobstructive or LM CAD. It may include up to [ADDRESS_774111] for research purposes.  
Withdrawal from the Study:  Complete and accurate follow -up is extremely important for the 
duration of the study . The participant , however, may decline to continue with their assigned 
management strategy at any time. This does not constitute withdrawal from the study. Participant s 
will continue to be followed per the assessment schedule. If at any time the subject refuses to 
continue with study visits, every attempt will be made to continue contact [CONTACT_107461], written 
communicat ion, email, by [CONTACT_587882], friends, or allied health care providers, or record 
review to determine if outcome events have occurred, unless the subject specifically refuses such 
follow -up. National databases that record deaths  will be used to  ascertain vital status , unless 
prohibited by [CONTACT_427] . The reason for (and the level of) withdrawal will be documented for 
all subjects withdrawn from the study or for those having limited follow -up. The subject must specify 
in writing what follo w-up (s)he will allow, if any, at the time of withdrawal discussion.  
 
Protocol Date: Jan.18. 2012          Version 1.0  39 Quality of Life (QOL) and Economics Overview  
Collection of Economic and QOL data, including the follow -up Full QOL Questionnaire validated 
scales will be repeated at 3, 12, 24 and 36  months from randomization and at the final ISCHEMIA 
visit by [CONTACT_587883]  (EQOLCC) for 
participant s enrolled in North America and by [CONTACT_587884].   A 
Proxy QOL questionnaire obtained from a relative, caretaker, or medical record will be used when a 
participant  has died in the follow -up interval, is too ill, otherwise incapacitated, or unable to 
participate. Lastly, a brief set of items capturing sel ected interval angina and dyspnea symptoms 
QOL (Brief/Symptom/QOL) will be collected by [CONTACT_587885] 36  months and then each 6 months until the final closeout 
ISCHEMIA visit .  All symptom and QOL data will be data processed and analyzed by [CONTACT_587886] .  A Hospi[INVESTIGATOR_587858] s at each follow -up study interval th roughout the 
trial to provide a measure of resource utilization.  Additionally, as part of the economic data in 
ISCHEMIA, medical bills for participant s enrolled at US sites only will be collected throughout the 
trial by [CONTACT_587887][INVESTIGATOR_51105]. The medical billing data 
will be obtained, extracted, data processed and analyzed by [CONTACT_587888].  
 
Protocol Date: Jan.18. 2012          Version 1.0  40 Table 4 Schedule of Study Assessments and Procedures (see Manual of Operations for visit windows)  
 
Screening visit  
CCTA visit  
Randomization visit  
(Baseline Visit)  
Catheterization & 
PCI or CABG  
Follow up  
     1.5mA 
Visit 1  3mA 
Visit 2  6mB 
Visit 3  12mA 
Visit 4  18mB 
Visit 5  24m  
Visit 6  30mB 
Visit 7  36mC 
Visit 8  Frequency 
beyond 36 
months  
Eligibility screen  X             
Informed consent (including biorepository 
consent if applicable)  X             
Creatinine and pregnancy testD  X             
Medical History/Medical Status  X  X  X X X X X X X X Q6m  
Cardiovascular medications  X  X  X X X X X X X X Q6m  
Transmit Stress Image to Core LabE X             
NYHA* and CCS class* * X  X  X X X X X X X X Q6m  
Release for medical records signed    X     X  X  X Q12m  
Coronary CT Angiography (CCTA)    XF            
Safety  assessment G  X  X          
Vital signs, weight, heightH   X  X X X X X X X X Q12m  
Standard lab resultsI    XJ  X X X X X X X X Q12m  
Biorepository blood draw    X   XK        
Cardiac biomarkersL     X          
Electrocardiogram (ECG) M   X XN    X  X   @ closeout  
Lifestyle Assessment (PACE)***    X   X  X  X  X Q12m  
Lifestyle Counseling (PACE)***    X  X X X X X X X X Q6m  
Modified Morisky Medication Adherence Survey    X    X X X X X X Q6m  
Full Quality of Life (QOL) assessment O   X   X  X  X  X @ closeout  
Brief symptoms/QOL assessmentP    X  X X X X X X X X Q6m  
Initiate Optimal Medical Therapy (OMT)    X           
Medical Therapy Evaluation and OptimizationQ     X X X X X X X X Q6m  
Schedule catheterization for INV participantsR   X           
Hospi[INVESTIGATOR_51105]      X X X X X X X X Q6m  
Endpoint assessment     X X X X X X X X X Q6m  
Follow -up visits will be scheduled based on time since the date of randomization  (baseline) .  
 
Protocol Date: Jan.18. 2012          Version 1.0  41 *NYHA - [LOCATION_001] Heart Association   **CCS - Canadian Cardiovascular Society     ***PACE - Patient -centered Assessment and Counseling for Exercise and nutrition (PACE) 
assessment and counseling     
                                                           
A 1.5, 3, and [ADDRESS_774112]  images ( immediately following enrollment and before randomization) , technical work sheets, and site interpretations/local reports  from qualifying stress tests 
to core labs . 
F CCTA not performed if estimated glomerular filtration rate < 60ml/min ; Blinded CCTA images  and technical worksheets  will be transferred to CCTA core lab for interpretation . 
G Safety Assessment (refer to section 14.4).  
H Height is only needed at randomization, assessments only required if visit is completed in clinic.  
I Required labs include: lipi[INVESTIGATOR_805] (preferably fasting), and liver transaminases (if indicated), and HbA1c (at visit 4, 6, 8 and annually thereafter for diabetic participants These lab 
results will be requested from the participant’s physician. If these results are not available they should be obtained by [CONTACT_587889]’s treating physician or stu dy staff.  
J Standard lab results needed at randomization include: complete blood count, electrolytes, creatinine, glucose, live r transaminases, lipid profile, HbA1c for diabetic participants .  
Request from participant’s physician, since i t is expected that  routine blood work will have been done within the last 6 months; if not  it will need to be done at this time.  
K May be requested . 
L For participants undergoing PCI: CK-MB at 8 -16 ± 2 hours or at hospi[INVESTIGATOR_2345], whichever comes earlier (troponin to be measured if CK -MB not available) . For participant s 
undergoing CABG : CK-MB at 18 ± 6 hours (troponin to be measured if CK -MB not available) . All biomarker measurements should be recorded on eCRF.  It is recommended to 
obtain a biomarker measurement before a ll PCI and CABG procedures.  
M Send to ECG core lab; ECG required for all cardiac admissions and revascularizations; year 1 ECG optional (filed on site) .  
N ECG done following procedure (60±[ADDRESS_774113] -CABG) . 
O Seattle Angina Questionnaire/Duke Activity Status Index/Rand general health status item/Perceived Stress Scale/Patient Health Questionnaire/Life Orientat ion Test –  
Revised/EQ -5D/Demographic characteristics . 
P Selected Seattle Angina Questionnaire/Rose dyspnea scale/EQ -5D. 
Q At every follow -up visit the research team, in collaboration with the treating physician(s), will evaluate effectiveness of medical therapy a nd optimize as needed according to 
guideline recommendations and study algorithms.  
R Planned cath and revascularization only  in the INV group.  See MOO for time windows for performing cath and revascularization after randomization.  Catheterization and 
optimal revascularization treatment should be targeted within 30 days after randomization in the Invasive strategy group. In th e Conservative group, catheterization and optimal 
revascularization is reserved for participant s with refractory angina symptoms or acute ischemic events.  
  
 
Protocol Date: Jan.18. 2012          Version 1.0  42  Screening visit  
• Patients with at least moderate ischemia by [CONTACT_587890] (see Table 1 ) will be 
assessed as potential study candidates  
• General medical and cardiac history will be reviewed for eligibility according to the 
inclusion/exclusion cr iteria in section 5.3  
• Willingness of both the prospective participant  and their physician for participation 
throughout the study will be confirmed  
• All screened prospective participant s will be recorded in the paper screening log 
• Prospective participants meeting clinical and site- based ischemia inclusion and 
exclusion criteria and interest ed in participating in the study will be consented for the 
study  
• Consented participants  with an eGFR ≥30ml/min will receive a study ID number via 
IVRS/IXRS. These participants  are considered “enrolled” (not randomized).  
• Creatinine testing if it has not been done within the last 90 days  
• Pregnancy test if premenopausal  
• For enrolled participant s stress testing images will be transferred electronically to the 
appropriate core laboratory. (see section 6.4 ) 
CCTA visit  
• For participant s with eGFR ≥ 60ml/min, blinded CCTA will be performed  
• Blinded CCTA images will be transferred to CCTA core lab for int erpretation 
• Participant s with eGFR 30 -59 ml/min do not require CCTA before randomization 
• Assessment for safety (e.g., complications of CCTA)  
Randomization visit (Baseline Visit)  (targeted within 15 days of participant ’s consent)   
• Confirm ischemia and CCTA eligibility  
• Medical history including CV medications will be documented  
• NYHA and CCS class (see MOO)  
• Brief symptoms/QOL assessment will be collected (prior to actual randomization)  
• Full QOL assessment will be collected (prior to actual randomization)  
 
Protocol Date: Jan.18. 2012          Version 1.0  43 • Modified Morisky medication adherence survey (see MOO)  
• Vital signs, height and weight will be measured  
• 12 lead ECG will be performed and sent to ECG core lab; stress ECG, and symptom, 
and hemodynamic results will be sent to ECG core lab 
• Results of routine laboratory tests performed within [ADDRESS_774114] results are not available a blood 
draw for routine laboratory tests will be done at this visit (see MOO)  
• Baseline blood draw for biomarker/genetics biorepositories  
• Eligible participant s will be randomized to INV or CON strategies via the IVRS/IXRS 
system. (These participant s are considered randomized)  
• Participant s randomized to INV strategy should target to undergo catheterization, with 
optimal revascularization to be completed within a target of 30 days from randomization 
• PACE will be implemented for all participant s 
• Initiate OMT in all randomized participant s according to guideline recommendations and 
study algorithms  
Cath and Revascularization for participant s randomized to INV strategy (protocol 
assigned); also applies to all revascularization procedures for participant s in both 
management strategies 
• For protocol assigned cardiac cath and revascularization (INV strate gy participant s), 
target completion within 30 days of randomization 
 
• Revascularization to be performed as per Optimal Revascularization Therapy (ORT) 
(refer to MOO)  
 
• For participant s under going PCI  
- [ADDRESS_774115] -PCI at 60 ± [ADDRESS_774116] pain  
- Blood draw for CK -MB at 8 -16 ± [ADDRESS_774117] -PCI or at hospi[INVESTIGATOR_2345], 
whichever comes earlier (troponin to be measured if CK -MB not available)  
- All pre- and post-procedure biomarker measurements that are obtained should 
be recorded on eCRF 
 
• For participant s undergoing CABG  
- [ADDRESS_774118] pain 
- Blood draw for CK -MB at 18 ± [ADDRESS_774119] -CABG (troponin to be measured if 
CK-MB not available)  
 
Protocol Date: Jan.18. [ADDRESS_774120]-procedure operative biomarker measurements that are obtained 
should be recorded on eCRF 
1.5 month  (6 week)  visit (Visit 1)  
• Medical status assessment  
• NYHA and CCS class (see MOO)  
• Vital signs and weight will be measured  
• Lifestyle counseling as per PACE will be performed 
• Brief symptoms/QOL assessment will be collected  
• Hospi[INVESTIGATOR_587859] 
• Endpoints will be assessed 
• Obtain lab results from participant ’s treating physician for lipi[INVESTIGATOR_805] (preferably fasti ng) and 
liver transaminases (when indicated). If not available these tests should be obtained by 
[CONTACT_102]’s treating physician or the study staff.  
• The study  team, in collaboration with the treating physician(s), will evaluate effectiveness 
of medical t herapy and optimize as needed according to guideline recommendations and 
study algorithms  
3 month visit  (Visit 2)  
• Medical status assessment  
• NYHA and CCS class (see MOO)  
• Vital signs and weight will be measured  
• Lifestyle assessment and counseling as per PACE  will be performed  
• Brief symptoms/QOL assessment will be collected  
• Full QOL assessment will be collected  
• Hospi[INVESTIGATOR_587859] 
• Biorepository blood draw will be performed  
• Endpoints will be assessed 
 
Protocol Date: Jan.18. 2012          Version 1.0  45 • Obtain lab results from participant ’s treating physician for lipi[INVESTIGATOR_805] (preferably fasting) and 
liver transaminases (when indicated). If not available these tests should be obtained by 
[CONTACT_2299] ’s treating physician or the study staff.  
• The study  team, in collaboration with the treating physician(s), will evaluate effectiveness 
of medical therapy and optimize as needed according to guideline recommendations and 
study algorithms  
6/18/30 month visits (Visits 3, 5, 7 respectively)  
• Medical status assessment  
• NYHA and CCS class (see MOO)  
• Vital signs and weight will be measured (only if clinic visit)  
• Modified Morisky medication adherence survey (see MOO)  
• Lifestyle counseling as per PACE will be performed 
• Brief symptoms/QOL assessment will be collected  
• Hospi[INVESTIGATOR_587859]  
• Endpoints will be assessed 
• Obtain lab results from participant ’s treating physician for lipi[INVESTIGATOR_805] (preferably fasting) and 
liver transaminases (when indicated). If not available these tests should be obtained by 
[CONTACT_2299] ’s treating physician or the s tudy staff.  
• The study  team, in collaboration with the treating physician(s), will evaluate effectiveness 
of medical therapy and optimize as needed according to guideline recommendations and 
study algorithms  
12/24/36 month visits (Visits 4, 6, 8 respectively)  
• Medical status assessment  
• NYHA and CCS class (see MOO)  
• Vital signs and weight will be measured  
• 12 lead ECG will be performed and submitted to core lab only at 24 month visit. Optional ECG to be retained at site at 12 months  
• Modified Morisky medication adherence survey (see MOO)  
• Lifestyle assessment and counseling as per PACE will be performed  
 
Protocol Date: Jan.18. 2012          Version 1.0  46 • Brief symptoms/QOL assessment will be collected  
• Full QOL assessment will be collected  (until 36 months)  
• Hospi[INVESTIGATOR_587859] 
• Endpoints will be assessed 
• Obtain lab results from participant ’s treating physician for lipi[INVESTIGATOR_805] (preferably fasting), liver 
transaminases (when indicated), and HbA1c for diabetic participants . If not available 
these tests should be obtained by [CONTACT_47992]’s treating physician or the study staff.  
• The study  team, in collaboration with the treating physician(s), will evaluate effectiveness 
of medical therapy and optimize as needed according to guideline recommendations and 
study algorithms  
Continuing Follow -Up Visits (every 6 months following the 36 month visit until close out)  
• Medical status assessment  
• NYHA and CCS class (see MOO)  
• Vital signs, and weight (only at every 12 month clinic visit)  
• Modified Morisky medication adherence survey  
• Lifestyle asses sment as per PACE (only at every 12 month visit)  
• Lifestyle counseling as per PACE  
• Brief symptoms/QOL assessment will be collected  
• Hospi[INVESTIGATOR_587859] 
• Endpoint will be assessed 
• Obtain lab results from participant ’s treating physician for lipi[INVESTIGATOR_805] (preferably fasting), liver 
transaminases (when indicated). HbA1c (only in participant s with diabetes at every 12 
month visit). If not available these tests should be obtained by [CONTACT_2299] ’s treating 
physician or the study staff.  
 
• The study  team, in collaboration with the treating physician(s), will evaluate effectiveness 
of medical therapy and optimize as needed according to guideline recommendations and 
study algorithms  
 
Protocol Date: Jan.18. 2012          Version 1.0  47 Close out visit (in addition to all assessment s for the regularly scheduled visit)  
• 12 lead ECG will be performed and submitted to core lab  
• Full QOL assessment will be collected  
• Obtain lab results from participant ’s treating physician for lipi[INVESTIGATOR_805] (preferably fasting) and 
HbA1c for diabetic participant s. If not available from the participant ’s treating physician 
these tests should be obtained by [CONTACT_2299] ’s treating physician or the study staff.  
 
 
 
 
Protocol Date: Jan.18. 2012          Version 1.0  48 11. ADJUDICATION OF CLINICAL EVENTS  
An independent clinical event adjudication committee (CEC) will review and adjudicate all 
primary endpoint events and selected secondary endpoints in a blinded fashion based on study 
definitions. Endpoints to be adjudicated include death (including cause),  myocardial infarction, 
resuscitated cardiac arrest, hospi[INVESTIGATOR_10929], hospi[INVESTIGATOR_19934], 
stroke, and transient ischemic attack. Because the trial is not blinded, to mitigate bias in the 
ascertainment of events, several s trategies will be used to identify (“trigger”) all suspected 
endpoints in all participant s including carefully constructed data collection tools that focus sites 
on key endpoint events, screening of ECG core lab data, site investigator and coordinator education about CEC procedures, and processing of events found by [CONTACT_587891]. Care will be taken to blind 
reviewers to any information that could identify the participant  or could reveal the randomized 
management strategy assignment. CEC members do not have access to mana gement strategy 
assignment in order to avoid bias, which is an important process issue in this unblinded trial.  
 
 
Protocol Date: Jan.18. 2012          Version 1.0  49 12. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN  
12.1 Sample Size Determination and Statistical Power  
12.1.1  Considerations and Assumptions  
The sample size of approximately 8,000 randomized participant s was selected to yield high 
power for testing the primary superiority hypothesis under reasonable assumptions about the 
frequency of the primary composite endpoint, the magnitude of the difference in event rates f or 
INV vs. CON strategies, and the pattern of accrual and dropout. Based on the distribution of 
coronary disease expected in this population (core- lab documentation of at least moderate 
ischemia; CCTA documentation of obstructive CAD) and based on unpublis hed data from the 
COURAGE trial and several observational stress imaging registries, the percent of participant s 
experiencing the primary composite endpoint within 4 years of randomization in the CON group was projected to be 20% (range 15% -25%). In additi on to the CON event rate, an additional key 
driver of the required sample size is the magnitude of benefit that can reasonably be expected 
to be achieved with the INV strategy. This determination was based on multiple factors including 
(i) effect size esti mates from related studies; (ii) anticipated increase in effect size by [CONTACT_587892]- obstructive CAD, (iii) potential for CON participant s to receive 
catheterization in violation of the protocol; and (iv) the investigators’ assessment of the m inimum 
effect size needed to be impactful and clinically relevant. After careful consideration of these and other factors, the sample size was formulated to provide high power to detect a 15% 
relative reduction (i.e., from 20% to 17% at 4 years) in the 4 -year rate of the primary composite 
endpoint for participant s randomized to INV versus CON (See Table 5
 footnote for other 
assumptions.) Recognizing that event rates and outcome differences in ISCHEMIA may differ somewhat from these as sumptions, the required sample size was also calculated for several 
different plausible combinations of parameter values. The final sample size was chosen to provide adequate power, even if our current assumptions prove to be optimistic. Loss of power due to protocol non -adherence was reflected in the sample size analysis by [CONTACT_587893] a relatively modest assumed treatment effect (20% vs.17%). Ideally, with perfect protocol 
adherence, a larger treatment effect would be plausible. Although the stud y objectives are 
worded in terms of testing a hypothesis (i.e. that the INV strategy is superior), another important 
objective is to estimate the magnitude of difference in outcomes (to within an acceptable level of statistical precision), regardless of which strategy (if either) is proven superior. Thus, the study is powered for precise parameter estimation (i.e. narrow confidence intervals) as well as 
hypothesis testing power.  
12.1.[ADDRESS_774121] ratio by 
[CONTACT_23818] a factor of 1.11 with probability 95% and will yield power ≥90% for comparing the 
primary composite endpoint across the two randomized groups assuming the 4 -year cumulative 
rate of the primary composite endpoint is 20% in participant s randomized to CON strategy and 
is less by a factor of 15% (i.e. is reduced from 20% to 17%) in participant s randomized to INV 
 
Protocol Date: Jan.18. 2012          Version 1.0  50 strategy. Power will be ≥80% if the 4 -year event rate of the primary composite endpoint is 
reduced by 13% instead of 15%, still assuming the 4- year rate is 20% in the CON strategy. 
Thus we have excellent power even with a more conservative effect size projection. Finally, 
power will be ≥80% if the 4- year cumulative rate of the primary composite endpoint is 15% 
instead of 20% in the CON strategy group, and is reduced by a factor of 15% in the INV strategy 
group. Thus, we have excellent power even with a more conservative estimate of the incidence 
of the  primary endpoint. Power and precision under other assumptions are summarized in Table 
5 and Table 6  below.  
 
Table 5.  Estimated Power as a Function of the Anticipated 4 -Year Cumulative Event 
Rate in CON and the 4-Year Cumulative Risk Reduction in INV (∆)  
CON anticipated 
4-year event rate  Estimated Power  
Event %  ∆ = 0.13  ∆ = 0.15  ∆ = 0.17  
10% 48% 60% 72% 
15% 67% 80% 89% 
20% 82% 92% 97% 
25% 92% 97% 99% 
30% 97% 99% ≥99%  
NOTE: ∆ denotes relative reduction in 4 -year event rate in INV vs. CON groups. Assumptions:  
Two-sided log- rank test with alpha = 0.05; 4000 participant s per group; average follow -up 3.7 
years; loss -to-follow -up 0.85% per year; survival times follow exponential distribution.  
 
Table 6. Range of Estimated Precision (Margin of Error) as a Function of the 
Anticipated 4 -Year Cumulative Event Rate in CON and the 4 -Year Cumulative Risk 
Reduction in INV (∆)  
CON anticipated 
4-year event rate  Margin of Error (MOE) 
Event %  ∆ = 0.13  ∆ = 0.15  ∆ = 0.17  
10% 1.16 1.16 1.16 
15% 1.13 1.13 1.13 
20% 1.11 1.11 1.11 
25% 1.10 1.10 1.10 
30% 1.09 1.09 1.09 
NOTE: MOE is the anti -log of the expected half -width of the 95% confidence interval for the log-
hazard ratio. Assumptions:  Based on a univariable Cox model with a binary treatment indicator 
and Wald- type 95% confidence intervals. See Table 5 for additional assumptions.  
 
 
Protocol Date: Jan.18. 2012          Version 1.0  51 12.2 Statistical Analysis Plan  
All major treatment comparisons between the randomized groups will be performed according to 
the principle of "intent -to-treat;" that is, participant s will be analyzed (and endpoints attributed) 
according to the randomized strategy, regardless of subsequent invasive testing or treatment. 
Statistical comparisons will be performed using two -sided significance tests. A statistical 
analysis plan will be finalized before trial completion and data analysis.  
12.2.[ADDRESS_774122] to the primary composite endpoint will be a “time -to-event” analysis, and will therefore be based on the time from 
randomization to the first occurrence of any of the components of the primary composite 
endpoint (CV death or nonfatal MI). The Cox proportional hazards will be the primary analytic 
tool for assessing outcome differences between the two randomized groups. To preserve power 
in the face of participant  heterogeneity, the overall comparison may be adjusted for a selected 
set of prognostically important baseline covariates that will be carefully defined and pre-
specified in the statistical analysis plan. The level of significance for the assessment of the 
primary endpoint will be α=0.05. In addition to Cox regression, event -free survival probabilities 
will be estimated as a function of follow -up time in each treatment group using the Kaplan- Meier 
method and presented with point wise 95% confidence interval s. If the data provide evidence of 
an overall difference in outcome between management strategy groups, we will further examine 
whether the therapeutic effect is similar for all participant s, or whether it varies according to 
specific participant  character istics, which will be pre -specified in the statistical analysis plan.  
 
12.2.2  Analysis of the Secondary Endpoints  
Secondary endpoints that will be evaluated include: (1) quality of life as measured by [CONTACT_587894]; (2) composite of cardiovascular death, nonfatal myocardial infarction, or stroke; (3) composite of cardiovascular death, nonfatal MI, 
resuscitated cardiac arrest, or hospi[INVESTIGATOR_587846]; ( 4) all-cause 
death; ( 5) CV death  ( 6) MI; ( 7) resuscitated cardiac arrest; ( 8) hospi[INVESTIGATOR_34104]; ( 9) hospi[INVESTIGATOR_19934]; (10) stroke; (1 1) composite of cardiovascular death, 
nonfatal MI, stroke, resuscitated cardiac arrest, or hospi[INVESTIGATOR_587846]; and (12 ) health resource utilization, cost, and cost effectiveness. Plans for the analysis 
of the quality of life and economic endpoints are addressed below in Sections 12.2.[ADDRESS_774123] occurrence of the specific secondary endpoint as the response variable.  
Unambiguous operational definitions of each study endpoint will be documented in the Clinical Event Committee Charter and statistical analysis plan before per forming unblinded analysis. For 
MI we will specify a primary definition (adapted from the universal definition of MI
57; to be used 
in the primary analysis of the primary and secondary endpoints). Other definitions (to be used in secondary analyses) will include the universal definition of MI and criteria to categorize large 
 
Protocol Date: Jan.18. 2012          Version 1.0  52 infarctions.  Data collection instruments and the adjudication process will allow construction of 
alternative endpoint MI definitions.  
 
12.2.3  Contingency Plan For Insufficient Primary Endpoint Events  
The projected event rate of 20% at [ADDRESS_774124] been accrued.  To 
ensure that the primary analysis is well -powered and useful, a prospective plan to allow 
extending follow -up and/or  changing the primary endpoint based on aggregate event rate data 
will be established prior to the first review of unblinded trial data . At a designated time during the 
trial, an analysis will be conducted to estimate the overall aggregate  primary endpoint event rate 
and project the final number of observed events. If the estimated unconditional  power (i.e. 
based on aggregate event rate data; not by [CONTACT_1570]) is less than the originally targeted 
90%, then one or more of the following options  will be considered:  
1. Extend follow -up to allow more events to accrue.  
2. Change the primary endpoint to one that occurs more frequently.  
• The current primary endpoint would become a secondary endpoint  
• The proposed new primary endpoint would be the composite of CV death, MI, 
resuscitated cardiac arrest, or hospi[INVESTIGATOR_587846].  
3. Follow the recommendation of an independent advisory panel.  
An independent advisory panel , separate from the DSMB,  will be convened for the purpos e of 
reviewing unconditional power estimates and making a recommendation to the NHLBI Director .  
Members of this panel will not have access to unblinded data by [CONTACT_587895].58, [ADDRESS_774125] unblinded interim 
analysis . 
12.2.4  Quality of Life (QOL) Analysis  
 
All QOL comparisons will adhere to the intention- to-treat principle. For each QOL measure 
examined in this study, data analysis will proceed in several stages. First, we will provide simple 
descriptive and comparative analyses by [CONTACT_7586]- to-treat. Statis tical power estimates for this 
part of our analysis, based on data collected in the COURAGE trial, show that we should have 
in excess of 99% power to detect ¼ SD differences in our [ADDRESS_774126] to deal with the multiple comparisons problem arising from testing 
 
Protocol Date: Jan.18. [ADDRESS_774127] and assign all other comparisons to a secondary (descriptive) status. Second, 
we will employ a mixed model methodology that makes use of all available QOL data at each 
study assessment point to model the time profile (fixed effect). Using the fitted model, we can 
estimate the overall difference in the QOL measures as well as  test the global hypothesis of no 
difference over time. We can also estimate the difference in the areas under the two QOL 
treatment curves (and test the hypothesis of no difference, on average). In addition, we can 
estimate differences in QOL at the end o f the study or at intermediate points.  Lastly, to address 
the possibility that international differences in QOL exist despi[INVESTIGATOR_587860], we will examine interactions between key QOL outcomes, treatment, and geographic region.  
 
12.2.[ADDRESS_774128] -effectiveness/cost -utility ratios, although these ratios are limited in their value due to 
their failure to account for long -term benefits  and costs and the absence of comparative 
benchmarks. Cost will be adjusted for inflation, and both costs and life expectancy will be discounted to present value at a 3% annual discount rate. Plots of cost -effectiveness 
acceptability curves indicating the probability that the intervention is cost -effective for a range of 
willingness -to-pay thresholds will be done. Extensive sensitivity analyses will be performed.  
12.2.[ADDRESS_774129] (DSMB) appointed by [CONTACT_587896] ( see 14.1
). The primary objective of these interim analyses is to ensure 
the safety of the participant s enrolled in the trial and evaluate the accumulating endpoint data by 
[CONTACT_587897]. In addition, interim monitoring will involve a review of participant  
recruitment, compliance with the study protocol, status of data collection, an assessment of 
 
Protocol Date: Jan.18. [ADDRESS_774130] available 
events, i.e., as adjudicated by [CONTACT_587898]/Investigator defined if the event has 
not yet been adjudicated by [CONTACT_142223]. The results of the interim analyses and status reports will be 
carefully and c onfidentially reviewed by [CONTACT_4318]. Detailed plans for interim monitoring will be 
documented in a separate DSMB analysis plan.  
Interim comparisons by [CONTACT_587899] -cause mortality and the primary 
composite endpoint (cardiovascular death and MI). Cox -proportional hazard models with 
treatment as the covariate will be used for the analysis. Estimates of hazard ratios and 95% 
confidence intervals comparing the INV and CON strategies will be reported. To account for 
repeated significance testing of the accumulating data, the group sequential method of Lan and 
DeMets60 will be used as a guide for interpreting these interim analyses. Monitoring boundaries 
for each endpoint will be based on a two- sided symmetric O’Brien -Fleming type spending 
function with an overall two- sided significance level of α = 0.05. The O’Brien- Fleming approach 
requires large critical values early in the study but relaxes (i.e., decreases) the critical value as the trial progresses.
61 These proposed monitoring boundaries are intended as a guide for 
interpreti ng the interim analyses and not as a rule for early termination.  
An additional key parameter for interim monitoring will be the frequency of early catheterization among participant s randomized to the CON strategy. Such catheterizations will be classified 
according to (1) whether the catheterization was allowed by [CONTACT_760] (e.g. for documented 
refractory symptoms) and (2) whether the catheterization was preceded by a nonfatal primary 
endpoint event (i.e., MI). A pattern of frequent early catheterization in CON participant s without 
prior endpoint events would suggest that the study may have difficulty achieving high statistical power. Moreover, if this was due to frequent protocol violations, then a finding of no treatment 
effect may be challenging to int erpret. To address these concerns, rates of early catheterization 
in the CON group will be analyzed and reported, with a focus on estimating the probability that a 
CON participant  will undergo catheterization within a specified time interval and before an 
endpoint event. To obtain this probability, the distribution of “time from randomization to catheterization” for CON participant s will be estimated using the cumulative incidence function 
method for competing risks.
[ADDRESS_774131] date or terminated after the participant ’s first primary e ndpoint event, whichever 
occurs first.  
Judgment concerning the continuation of the study will involve not only the magnitude of 
observed differences between randomized strategies and degree of statistical significance, but 
also careful consideration of many other important factors including the need for precise 
parameter estimation, the overall progress and integrity of the trial (including the frequency of catheterization in the CON group, as discussed above), and information available from other 
studies at the time of DSMB deliberations. If a stoppi[INVESTIGATOR_587861], 
this result should be tempered by [CONTACT_587900], but long -term benefit. Although we hypothesize that outcomes will be improved by [CONTACT_587901]: Jan.18. [ADDRESS_774132] for the primary endpoint is 
not necessarily a negative result for the study. Indeed, evidence suggesting absence of a large 
benefit from the invasive strategy would be highly important to future guidelines and c linical 
practice. However, a large sample size is required in order to derive such evidence. If the study were to be stopped early with less than the full sample size, the lack of statistically significant 
difference may be accompanied by [CONTACT_587902] i ntervals and no clear conclusion might be 
possible. The DSMB will incorporate this perspective along with other considerations when 
making recommendations about continuation.  
 
 
Protocol Date: Jan.18. [ADDRESS_774133] KEEPI[INVESTIGATOR_1645]  
13.1 Electronic Data Capture (EDC) System  
 
The full  study dataset will be collected for participant s who enter the randomized phase of the 
study. The primary data collection system for ISCHEMIA will use a web- based electronic data 
capture (EDC) system, a validated Electronic Record, Electronic Signatures (ERES) compliant 
platform (21 CFR Part 11). All these data collected at any point in the trial except the economic 
and quality of life information, are entered into this EDC system.  
 
13.2 Data Management and Quality  
 
Any out -of-range values and missing or inconsistent key variables will be flagged and 
addressed at the site in real time during the data entry process. When a query is generated on a 
particular variable, a flag will be set in a field in the database enabling the system to track the 
queries and produce reports of outstanding queries.  Queries can also be generated from manual review of the data forms.  These queries will be entered into the database and tracked in the same manner as the computer -generated queries.  At regular intervals, all data will be 
transferred from the EDC database to SAS for statistical summarization, data description, and 
data analysis.  Further cross -checking of the data will be performed in SAS, and discrepant 
observations flagged and appropriately resolved through a data quer y system. The Statistical 
and Data Coordinating Center (SDCC) will perform internal database quality -control checks, and 
data audits throughout the course of the trial.  
 
13.[ADDRESS_774134] and report all access to data. The DCRI computer network is protected by a firewall.  
Electronic CRFs (eCRFs) will be identified by [CONTACT_34161], to e nsure participant  
anonymity. No participant  identi fiers will be used in the presentation of data. Study records that 
might identify participant s will be kept confidential as required by [CONTACT_2371]. Except when required by 
[CONTACT_2371], participant s will not be identified by [CONTACT_2300], personal identification number (e.g. soci al 
security number, social insurance number), address, telephone number, or any other direct personal identifier in study records. This information will be retained by [CONTACT_587903], quality of life and economic follow -up of the participant s. Participant s will be informed that the 
study physician and his/her study team will report the results of study -related tests to the 
Coordinating Center and to the NI H. Participant s will be informed that their records may be 
reviewed in order to meet federal, state or regional/local regulations. Reviewers may include the 
CCC/SDCC monitors, IRBs/ECs, the NIH, other government regulators as dictated by [CONTACT_1769], 
or thei r delegates.  
Images will be stripped of identifiers present within the DICOM header during the image upload process, by a vendor which will be responsible for image transfer and storage for this trial.
 
 
Protocol Date: Jan.18. 2012          Version 1.0  57 13.4 Training  
 
All investigational site and core lab staff authorized to enter ISCHEMIA Study data will receive 
training on the EDC system. Training records will be retained by [CONTACT_587904].  
 
13.5 Records Retention  
 
Study records will be maintained by [CONTACT_408111] a period of six ( 6) years following 
the expi[INVESTIGATOR_408099], whichever is longer.  
 
13.6 Management of Economic and Quality of Life (EQOL) Data  
The economic and quality of life studies will be fully integrated into the clinical trial and will be 
covered by [CONTACT_587905]. Interviewers will be blinded to the study 
group. Data processing, quality control, and analysis of EQOL data will be performed by [CONTACT_587906] s. Although the EQOL computer network is not a regulated environment as are the 
clinical databases, EQOL follows the same network security protocols including password 
protection, expi[INVESTIGATOR_587862], and restricted access. Participant  information records will be kept 
confidential in a separate, secured SQL Server database, and the participant ’s name [CONTACT_587926]. Even though the interviewers must be unblinded to participant  identity in order to 
collect the EQOL data, unblinded information is locked with restricted access, and none of the 
electronic databases or analysis files include direct participant  identifiers. The electronic 
databases have (coded) study identifiers. In addition to participant  identifiers never being linked 
to the clinical database, they are never passed on to the sponsor or third party. The interviewers 
obtain an approved Duke University IRB required consent from the participant  on the telephone 
before a questionnaire may be administered. All of the EQOL data are analyzed in aggregat e 
with only coded study identifiers (no direct participant  identifiers), and no individual 
data/ participant  identifier will ever be presented in any oral or written form. No name [CONTACT_587927] t he study.  
 
Protocol Date: Jan.18. [ADDRESS_774135] (DSMB) will be appointed by [CONTACT_587907]. A DSMB charter that outlines the 
operating gui delines for the committee and the procedures for the interim evaluations of study 
data will be developed by [CONTACT_587908]. Reports will be prepared regularly by [CONTACT_587909], and will include interim analyses of primary and secondary endpoints; 
additional safety events; and other information as requested by [CONTACT_942]. After each 
meeting, the DSMB will make recommendations to the NHLBI and the trial  leadership about the 
continuation of the study. After approval by [CONTACT_587910], a summary of the DSMB report 
and recommendations will be forwarded by [CONTACT_587911], regional and national IRB/Ethics Committees , as applicable. DSMB reports will be the 
primary mechanism for reporting safety concerns to NIH and IRBs.
 
 
14.[ADDRESS_774136] of care when used in the testing 
sequence in the trial. The risk of cath and revascularization will be minimized by [CONTACT_587912]. These risks  are justified by [CONTACT_587913] (long -term reduction in events resulting from revascularization, as discussed in 
the background section).  
 
Risks:  
 
CCTA Risks: The primary risk is an increased exposure to radiation from the CCTA scan.  On 
average, t he estimated total radiation dose from this study (one CCTA scan) will range from  4-8 
mSv. In comparison, other estimated doses of medical radiation include: chest X -ray (0.05 
mSv); invasive cardiac catheterization (5- 7 mSv); PCI (10 -16 mSv); nuclear stress test (12 -30 
mSv). In [ADDRESS_774137] will not be included in the 
study. As noted above participant s with eGFR  30-59 ml/min will not undergo CCTA to minimize 
risk from this procedure in the trial. Patients with eGFR<30 ml/min will be excluded. Beta 
blockade, which is routinely used during CCTA, may cause bradycardia, hypotension or 
 
Protocol Date: Jan.18. [ADDRESS_774138] docu mented before 
undergoing the CCTA or being placed into either of the two study groups.  
 
Cath/PCI/CABG Risks: Each of these procedures is commonly performed in clinical practice for 
patients who meet eligibility criteria for the study. The major risks of these procedures include 
death, myocardial infarction and stroke. Other risks of catheterization and PCI include  severe 
contrast reaction such as anaphylaxis, emergency CABG, bleeding, need for blood transfusion, contrast -induced nephropathy and vascular ac cess site complications including 
pseudoaneurysm, AV fistula, retroperitoneal bleed or infection. Other risks of CABG include return to operating room for bleeding, need for blood transfusion, infection, prolonged intubation, mediastinitis and atrial fibri llation . Risks of these procedures vary in likelihood based on the 
patient’s risk profile.  
 
Risk Lowering Measures:  
Study procedures are designed to manage and minimize risks through careful selection of the 
patients who participate in the trial. Participant s will be monitored closely through the trial at 
many time points to check on their health. In addition, an independent DSMB will monitor safety 
of the participant s throughout the study (see section 14.1
) 
Benefits:  
The IS CHEMIA trial results should provide evidence based data to support management of 
patients with SIHD.  
There may be benefit from participation in this study by [CONTACT_587914] s as well as involvement of an 
additional team following the participant s’ health status. Participant s may receive some 
medications and stents free of cost, as available. It is hoped the knowledge gained will be of benefit to others with a similar medical condition in the future.  
 
14.3 Safety Monitoring Objectives and Rationale  
The main safety objectives in ISCHEMIA are to characterize the risk profiles of the two 
randomized management strategies and to monitor for unanticipated risks to study participants. 
All medications and procedures to be used/performed in this study are commonly 
used/performed for clinical indications as part of standard of care and have well -defined safety 
profiles. Because no investigational device, drug, diagnostic test or therapeutic intervention is 
being tested in this comparative effectiveness trial, reporting is primarily governed by [CONTACT_587915] (45 CFR Part 46, Subpart A), as well as ICH Guidelines, IRBs and local regulations.  
 
Protocol Date: Jan.18. 2012          Version 1.0  60 14.4 Adverse Events Reporting by [CONTACT_587916] m onitoring participants’ safety will be captured within the EDC database as part of the 
required study data. There are no additional study -specific reporting requirements. Site 
investigators should follow usual clinical practices at their institutions for r eporting serious, 
unexpected events related to standard of care medications and devices to regulatory agencies.  
14.5 Events to be Monitored 
 
Safety monitoring in ISCHEMIA will be concerned with estimating event rates for the following 
types of clinical events:  
1. Complications of cardiovascular tests (e.g. CT coronary angiogram, cardiac 
catheterization) and therapeutic procedures (e.g. PCI, CABG)  
2. Events occurring in the time period between consenting to participate in the trial and 
being randomized.  
3. Study endpoints.  
1. Complications of cardiovascular tests and therapeutic procedures  
All drugs, diagnostic tests and therapeutic procedures to be used in this trial have been 
extensively evaluated previously, have established safety profiles with known risks and benefi ts 
and are routinely used in clinical practice.  Events listed below occurring within 72 hours of the 
procedure will be considered as a complication of the procedure.  Some safety events related to 
specific tests and procedures captured within EDC , in addi tion to death and MI , include:  
CT coronary angiography:  
1. Severe contrast reaction such as anaphylaxis  
2. Hemodynamic instability, including symptomatic bradycardia or hypotension, due to the 
beta blockade or nitrates given for the CCTA scan acquisition  
3. Acute bronchospasm due to the beta blockade given for the CCTA scan  
4. Contrast induced nephropathy  
5. Radiation dose exposure  
 
In addition the incidence of finding significant LM stenosis ( >50%) on cardiac catheterization not 
reported on CT coronary angiogram will be monitored and reported to the DSMB. Incidental 
findings on CCTA that are of clinical importance (e.g.,  aortic aneurysm or suspected neoplasm) 
will be reported to the site and the participant  may be excluded from the study.  
Cardiac catheterization and PCI : 
1. Severe contrast reaction such as anaphylaxis  
2. Periprocedural stroke  
3. Emergency CABG  
4. Contrast -induced nephropathy  
 
Protocol Date: Jan.18. 2012          Version 1.0  61 5. Vascular access site complications including pseudoaneurysm, AV fistula, 
retroperitoneal bleed  
 
CABG:  
1. Return to operating room for bleeding 
2. Prolonged intubation  
3. Mediastinitis  
4. Atrial fibrillation  
 
2. Events occurring in the time period between consent and randomization  
In general, eligibility for randomization will not be known at the time of enrollment but will need 
to be confirmed after performing additional screening procedures (e. g. pregnancy test and 
blinded CCTA ). As a result, several days may elapse before the participant  is randomized. 
Frequency of clinical events  (e.g. death, MI) occurring during this time period, prior to 
randomization,  will be monitored and reported to the DSMB.  
 
3. Events that are trial endpoints  
Selected trial endpoints (e.g. all -cause mortality) will be monitored at regular intervals during the 
course of the trial for the purpose of protecting participants’ safety. Event rates in each 
treatment group will be confidentially reviewed by [CONTACT_4318]. These analyses will inform the 
DSMB’s recommendation to stop or continue the study or modify the protocol (see section 
12.2.6 ). 
 
Protocol Date: Jan.18. 2012          Version 1.0  62 15. ETHICAL CONSIDERATIONS  
15.1 Regulatory and Ethical Compliance  
 
This clinical study was designed and shall be implemented and reported in accordance with the 
international conference on harmonization (ICH) Harmonized Tripartite Guidelines for Good 
Clinical Practice, with  applicable local regulations (including European Directive 2001/20/EC, 
US Code of Federal Regulations Title 45 and Japanese Ministry of Health, Labor, and Welfare), 
and with the ethical principles laid down in the Declaration of Helsinki.  
 
15.[ADDRESS_774139] be obtained from every participant  or, in 
those sit uations where consent cannot be given by [CONTACT_3445] s, their legally acceptable 
representative, prior to clinical study participation, including informed consent for any screening procedures conducted to establish participant  eligibility for the study (e.g . CCTA). The rights, 
safety, and well -being of the study participants  are the most important considerations and 
should prevail over interests of science and society. Women of child bearing potential will be 
informed that there may be unknown risks to the f etus if pregnancy were to occur during the 
study and they were exposed to radiation (e.g. CCTA and cardiac catheterization and revascularization if randomized to the INV strategy group) and agree that in order to participate 
in the study they must adhere t o the contraception requirement during this period of the study. If 
there is any question that the prospective participant  will not reliably comply with study 
procedures and/or follow- up, they should not be entered in the study.  
15.3 Responsibilities of the Inv estigator and IRB/IEC/REB  
The protocol and the proposed informed consent forms (main consent form and genetics testing 
consent form) will be reviewed and approved by a properly constituted Institutional Review 
Board/Independent Ethics Committee/Research Et hics Board (IRB/IEC/REB) at each site. A 
signed and dated statement that the protocol and informed consent have been approved by [CONTACT_5040]/IEC/REB is required before site initiation. A separate IRB/IEC/REB waiver of consent may also be required for the screening survey, according to local regulations. Prior to study start, the 
site principal investigator [INVESTIGATOR_587863] a protocol signature [CONTACT_5389]/her 
agreement to conduct the study in accordance with these documents and all of the instructions 
and procedures found in this protocol and to give access to all relevant data and records to 
monitors, auditors, Clinical Quality Assurance representatives, designated agents of CCC, 
IRBs/IECs/REBs, and regulatory authorities as required. Investigators m ust agree to apply due 
diligence to avoid protocol deviations.  
 
  
 
Protocol Date: Jan.18. [ADDRESS_774140] be approved by [CONTACT_323238], Health Authorities where required, and the IRB/IEC /REB. Only 
amendments that are required for participant  safety may be implemented prior to IRB/IEC/REB 
approval. As soon as possible, the implemented deviation or change, the reasons for it and, if 
appropriate, the proposed protocol amendment(s) will be submitted: (a) to the IRB/IEC/REB for 
review and approval/favorable opi[INVESTIGATOR_1649]; (b) to the sponsor, NIH/NHLBI for agreement; and, if 
required, (c) to the regulatory authority(ies). Notwithstanding the need for approval of formal 
protocol amendments, the investi gator is expected to take any immediate action required for the 
safety of any participant  included in this study, even if this action represents a deviation from the 
protocol. In such cases, CCC should be notified of this action and the IRB/IEC/REB at the study 
site should be informed.  
 
15.5 Early Termination of the Study  
The CCC and NHLBI retain the right to terminate the study, a study site or an investigator at any 
time. The CCC will monitor the progress of the study. If warranted, the study may be suspended 
or discontinued early if there is an observation of safety conc erns posing an unreasonable risk 
to the study population. If the study is terminated early, the CCC will provide a written statement 
to the site Principal Investigators to enable notification to site IRBs/IECs/REBs and study 
participants . The CCC will also inform the appropriate Competent Authorities. The CCC may 
terminate enrollment activity at a site, or participation in the study by [CONTACT_587917]’s failure to maintain adequate clinical standards or failure to 
comply with the protocol. Notification of enrollment suspension or termination of the study or study site/investigator will be sent to the investigator and the IRBs/IECs/REBs.  
 
 
 
Protocol Date: Jan.18. 2012          Version 1.0  64 16. STUDY ORGANIZATION  
ISCHEMIA is sponsored by [CONTACT_587918], Lung, and Blood Institute (NHLBI). The 
Clinical Coordinating Center (CCC), S tudy Chair, and Study Co- Chair maintain responsibility for 
the overall conduct of the study, including site management and site monitoring in participating 
countries, analysis and reporting.  The Statistical and Data Coordinating Center (SDCC) is 
responsible for the treatment allocations of eligible participant s, receipt and processing of data 
collected by [CONTACT_145889], core laboratories and coordinating center s, quality control 
programs, and statistical analysis and reporting. The Ischemia Imaging Coordinating Center 
(ICC) will organize and oversee the stress imaging core laboratories, coordinate and implement 
educational systems for sites and monitor site s tress imaging performance. The Economics and 
Quality of Life Coordinating Center (EQOLCC) is responsible for the conduct of the quality of life and the economics and cost effectiveness portions of this study. The Computed Tomography 
Coronary Angiography Core Laboratory (CCTA CL) will interpret all CCTA scans and will 
provide technical support. The angiographic core laboratories (ACL) will characterize coronary 
anatomy for participant s undergoing coronary angiography and procedural outcomes for those 
undergoing PCI. Members of  the NHLBI will participate in the study leadership. Details 
regarding the Cores and Coordinating Centers may be found in the MOO.  
Details of the Committees, their charge and membership may be found in the MOO. These 
Committees include Leadership, Executive and Steering Committees, optimal medical therapy 
and optimal revascularization committees, committee on recruitment of women and minorities, 
biorepository, statistics, ancillary studies and publications committees.  
 
Protocol Date: Jan.18. [ADDRESS_774141] submit a proposal requesting approval to access ISCHEMIA trial data/specimens. The 
ISCHEMIA trial will participate in the NHLBI Central Repository for study data and speci mens.  
All data access will follow guidelines described in the NHLBI Limited Access Data Policy 
(www.nhlbi.nih.gov/resources/deca/policy_new.htm ), the NIH Data Sharing Policy 
(http://grants.nih.gov/grants/gwas/index.htm ), and the Policy for Sharing of Data Obtained in 
NIH Supported or Conducted Genome- Wide Association Studies (GWAS) 
http://grants.nih.gov/grants/gwas/index.htm ) with regard to documentation, content, storage and 
timing.  
 
Protocol Date: Jan.18. 2012          Version 1.0  66 18. PUBLICATIONS POLICY: OVERVIEW  
Primary and secondary reports of study findings will be published in peer -reviewed journals. 
Proposals for presentations and publications incorporating data obtained from participant s 
involved in the ISCHEMIA trial must be submitted for review by [CONTACT_242215].  The 
primary publication will be authored by [CONTACT_20767]’s writing committee.  No site is perm itted to 
present or publish data obtained during the conduct of this trial without prior approval from the 
publications committee. Authorship for ISCHEMIA -related publications will be determined by [CONTACT_587919]. 
The full publications policy may be found in the MOO.  
  
 
Protocol Date: Jan.18. [ADDRESS_774142] 
V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, 
Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, 
Roger VL, Thom T, Wasserthiel -Smoller S, Wong ND, W ylie-Rosett J. Heart disease and 
stroke statistics --2010 update: A report from the american heart association. Circulation . 
2010;121:e46 -e215  
2. WHO.  
3. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, 
Passamani E, Norris R, et al. Effect of coronary artery by[CONTACT_587920]: 
Overview of 10- year results from randomised trials by [CONTACT_587921]. Lancet . 1994;344:563- 570 
4. Coronary artery surgery study (cass): A randomized trial of coronary artery by[CONTACT_4897]. Survival data. Circulation . 1983;68:939 -950 
5. Eleven- year survival in the veterans administration r andomized trial of coronary by[CONTACT_587922]. The veterans administration coronary artery by[CONTACT_587923]. The New England journal of medicine. 1984;311:1333- 1339  
6. Varnauskas E. Twelve- year follow -up of survival in the randomized european coronary 
surgery study. The New England journal of medicine. 1988;319:332- 337 
7. O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS, Jr., 
Hennekens CH. An overview of randomized trials of rehabilitation with exercise after 
myocardial infarction. Circulation . 1989;80:234 -244 
8. Oldridge NB, Guyatt GH, Fischer ME , Rimm AA. Cardiac rehabilitation after myocardial 
infarction. Combined experience of randomized clinical trials. Jama . 1988;260:945- 950 
9. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, 
traditional risk factors, and the rate of cardiovascular complications after myocardial 
infarction: Final report of the lyon diet heart study. Circulation . 1999;99:779 -785 
10. Leren P. The oslo diet -heart study. Eleven- year report. Circulation . 1970;42:935- 942 
11. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: A systematic review. Jama. 2003;290:86- 97 
12. Lau J, Antman EM, Jimenez -Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative 
meta -analysis of therapeutic trials for myocardial infarction. The New England journal of 
medicine. 1992;327:248 -254 
13. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovas c Dis . 
1985;27:335 -371 
14. Al-Mallah MH, Tleyjeh IM, Abdel -Latif AA, Weaver WD. Angiotensin- converting enzyme 
inhibitors in coronary artery disease and preserved left ventricular systolic function: A 
systematic review and meta- analysis of randomized controlled trials. Journal of the 
American College of Cardiology . 2006;47:1576- 1583 
15. Collaborative meta- analysis of randomised trials of antiplatelet therapy for prevention of 
death, myocardial infarction, and stroke in high risk patients. BMJ (Clinical resea rch ed . 
2002;324:71 -86 
16. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, 
Peto R, Collins R, Simes R. Efficacy and safety of cholesterol -lowering treatment: 
Prospective meta- analysis of data from 90,056 participants in 14 randomised trials of 
statins. Lancet . 2005;366:1267- 1278  
 
Protocol Date: Jan.18. 2012          Version 1.0  68 17. Khalil ME, Basher AW, Brown EJ, Jr., Alhaddad IA. A remarkable medical story: Benefits 
of angiotensin -converting enzyme inhibitors in cardiac patients. Journal of the American 
College of Cardiology . 2001;37:1757 -1764  
18. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, 
Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant 
vitamins, or the combination for the prevention of coronary disease. The New England 
journal of medicine. 2001;345:1583 -1592  
19. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial 
intervention and cardiovascular disease in patients with type 2 diabetes. The New 
England journal of medicine. 2003;348:383- [ADDRESS_774143] (scrip). 
Circulation . 1994;89:[ADDRESS_774144] G, 
Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, 
O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL. 
Coronary -artery by[CONTACT_587924]. The New 
England journal of medicine. 2011;364:1607- [ADDRESS_774145] T, Michler RE, Berman DS, Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ, Jones RH, Panza JA. Myocardial v iability and survival in ischemic left ventricular dysfunction. The New 
England journal of medicine. 2011;364:1617- 1625  
23. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, 
Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title 
LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS. Optim al medical therapy with or without pci for stable coronary disease. 
The New England journal of medicine. 2007;356:1503- [ADDRESS_774146] TJ, 
Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, 
Sako EY, Sobel BE. A randomized trial of therapi[INVESTIGATOR_36259] 2 diabetes and coronary 
artery disease. The New England journal of medicine. 2009;360:2503- 2515  
25. Lucas FL, Siewers AE, Malenka DJ, Wennberg DE. Diagnostic -therapeutic cascade 
revisited: Coronary angiography, coronary artery by[CONTACT_10956], and 
percutaneous coronary intervention in the modern era. Circulation . 2008;118:2797- 2802  
26. Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation 
between clinical and angiographic findings in ischemic heart disease. Circulation . 
1995;92:[ADDRESS_774147] -time elective percutaneous coronary 
revascularization. J Gen Intern Med. 2000;15:632 -637 
28. Lin GA, Dudley RA, Redberg RF. Cardiologists' use of percutaneous coronary 
interventions for stable coronary artery disease. Arch Intern Med. 2007;167:1604- 1609  
29. Marwick TH, Shaw LJ, Lauer MS, Kesler K, Hachamovitch R, Heller GV, Travin MI, 
Borges -Neto S, Berman DS, Miller DD. The noninvasive prediction of cardiac mortality in 
men and women with known or suspected coronary artery disease. Economics of noninvasive diagnosis (end) study gr oup. Am J Med . 1999;106:172 -178 
30. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. Journal 
of the American College of Cardiology . 2006;47:C13- 18 
 
Protocol Date: Jan.18. 2012          Version 1.0  69 31. Shah PK. Mechanisms of plaque vulnerability and rupture. Journal of the Amer ican 
College of Cardiology . 2003;41:15S -22S 
32. Fuster V, Badimon J, Chesebro JH, Fallon JT. Plaque rupture, thrombosis, and 
therapeutic implications. Haemostasis . 1996;[ADDRESS_774148] 4:269- 284 
33. Shin J, Edelberg JE, Hong MK. Vulnerable atherosclerotic plaque:  Clinical implications. 
Current vascular pharmacology . 2003;1:183 -204 
34. Alderman EL, Corley SD, Fisher LD, Chaitman BR, Faxon DP, Foster ED, Killip T, Sosa 
JA, Bourassa MG. Five- year angiographic follow -up of factors associated with 
progression of coronary artery disease in the coronary artery surgery study (cass). Cass partic ipating investigators and staff. Journal of the American College of Cardiology . 
1993;22:1141 -1154  
35. Hachamovitch R, Kang X, Amanullah AM, Abidov A, Hayes SW, Friedman JD, Cohen I, 
Thomson LE, Germano G, Berman DS. Prognostic implications of myocardial perfusion 
single -photon emission computed tomography in the elderly. Circulation . 2009;120:2197 -
2206 
36. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the 
short -term survival benefit associated with revascularization compared with medical 
therapy in patients with no prior coronary artery disease undergoing stress myocardial 
perfusion single photon emission computed tomography. Circulation . 2003;107:2900 -
2907 
37. Hachamovitch R, Rozanski A, Hayes SW, Thomson LE, Germano G, Friedman J D, 
Cohen I, Berman DS. Predicting therapeutic benefit from myocardial revascularization procedures: Are measurements of both resting left ventricular ejection fraction and stress -induced myocardial ischemia necessary? J Nucl Cardiol. 2006;13:768- 778 
38. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, 
O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, 
Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, 
Bates ER, McCalliste r B, Teo KK, Boden WE. Optimal medical therapy with or without 
percutaneous coronary intervention to reduce ischemic burden: Results from the clinical 
outcomes utilizing revascularization and aggressive drug evaluation (courage) trial 
nuclear substudy. Cir culation. 2008;117:[ADDRESS_774149] on exercise single-photon emission computed tomographic thallium imaging on patient management and 
outcome. J Nucl Cardiol. 1995;2:334- 338 
40. Bateman TM, O'Ke efe JH, Jr., Dong VM, Barnhart C, Ligon RW. Coronary angiographic 
rates after stress single- photon emission computed tomographic scintigraphy. J Nucl 
Cardiol . 1995;2:217- 223 
41. Shaw LJ, Hachamovitch R, Berman DS, Marwick TH, Lauer MS, Heller GV, Iskandrian 
AE, Kesler KL, Travin MI, Lewin HC, Hendel RC, Borges -Neto S, Miller DD. The 
economic consequences of available diagnostic and prognostic strategies for the 
evaluation of stable angina patients: An observational assessment of the value of 
precatheterizat ion ischemia. Economics of noninvasive diagnosis (end) multicenter study 
group. Journal of the American College of Cardiology . 1999;33:661 -669 
42. Hachamovitch R, Johnson J, Hlatky MA, Branscomb E, Ridner ML, Beanlands RS, 
Chow BJ, Berman DS, Shaw L, Lesser J, Chareonthaitawee P, Johnson BD, Gaber M, 
Hainer J, Di Carli M. Short -term referral rates to catheterization after noninvasive cardiac 
imaging: Results from the study of myocardial perfusion and coronary anatomy imaging roles in cad (sparc) trial 90 day follow -up. Circulation . 2009;120:S486  
43. Berman DS, Kang X, Hayes SW, Friedman JD, Cohen I, Abidov A, Shaw LJ, Amanullah 
AM, Germano G, Hachamovitch R. Adenosine myocardial perfusion single- photon 
emission computed tomography in women compared with men. Impact of diabetes 
 
Protocol Date: Jan.18. [ADDRESS_774150] on patient management. Journal of 
the American College of Cardiology . 2003;41:1125- [ADDRESS_774151] 
effective in risk stratification of patients with a high likelihood of coronary artery disease 
(cad) but no known cad. Journal of the American College of Cardiology . 2004;43:[ADDRESS_774152] catheterization of patients with reduced left ventricular 
ejection fraction? Influence of ejection fraction and inducible ischemia on post -single -
photon emission computed tomography manage ment of patients without a history of 
coronary artery disease. Journal of the American College of Cardiology . 2003;42:[ADDRESS_774153] pain patients. The economics 
of noninvasive diagnosis (end) study group. The American journal of cardiology . 
2000;86:[ADDRESS_774154], Majmundar H, Thomas JJ, Sampson CH, 
Hachamovitch R, Shaw LJ. Technetium 99m sestamibi myocardial perfusion imaging 
predicts clinical outcome in the community outpatient setting. The nuclear utility in the 
community (nuc) study. Journal of the Ame rican College of Cardiology . 2004;43:[ADDRESS_774155] of 
a standardized quality -improvement protocol on radiation dose in coronary computed 
tomographic angiography. The Ameri can journal of cardiology . 2010 (in press)  
49. Leipsic J, Labounty TM, Heilbron B, Min JK, Mancini GB, Lin FY, Taylor C, Dunning A, 
Earls JP. Adaptive statistical iterative reconstruction: Assessment of image noise and 
image quality in coronary ct angiography. AJR Am J Roentgenol . 2010;195:649- [ADDRESS_774156] angiography. AJR Am J Roentgenol . 2010;194:933- [ADDRESS_774157] of a standardized radiation dose reduction protocol on diagnostic accuracy of 
coronary computed tomographic angiography. The American journal of cardiology . 
2010;106:[ADDRESS_774158] angiography: The erasir study. AJR Am J Roentgenol . 
2010;195:[ADDRESS_774159], Edelman D, Bosworth HB. Is there a nonadherent 
subtype of hypertensive patient? A latent class analysis approach. Patient preference 
and adherence . 2010;4:255- 262 
54. Bosworth HB, Olsen MK, Grubber JM, Neary AM, Orr MM, Powers BJ, Adams MB, 
Svetkey LP, Reed SD, Li Y, Dolor RJ, Oddone EZ. Two self -management interventions 
to improve hypertension control: A randomized trial. Annals of internal medicine. 
2009;151:687 -695 
55. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self -reported 
measure of medication adherence. Medical care . 1986;24:67 -74 
 
Protocol Date: Jan.18. 2012          Version 1.0  71 56. Lowry KP, Dudley  TK, Oddone EZ, Bosworth HB. Intentional and unintentional 
nonadherence to antihypertensive medication. The Annals of pharmacotherapy . 
2005;39:1198 -1203  
57. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby [CONTACT_170284], 
Ravkilde J, Cha itman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, 
Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, 
Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, 
Ohman EM, Simoons ML, Poole- Wilson PA, Gurfinkel EP, Lopez -Sendon JL, Pais P, 
Mendis S, Zhu JR, Wallentin LC, Fernandez -Aviles F, Fox KM, Parkhomenko AN, Priori 
SG, Tendera M, Voipio- Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, 
Dickstein K, Filippatos G, Funck -Brentano C, Hellemans I, Kristensen SD, McGregor K, 
Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, 
Harrington R, Morrow D, Lim M, Martinez -Rios MA, Steinhubl S, Levine GN, Gibler WB, 
Goff D, Tubaro M, Dudek D, Al -Attar N. Universal definition of myocardial infarction. 
Circulation . 2007;116:2634- 2653  
58. Wittes J. On changing a long- term clinical trial midstream. Statistics in medicine . 
2002;21:2789 -2795  
59. S. E. When and how can endpoints be changed after initiation of a randomized clinical 
trial? PLoS Clin Trials.  2007;2:e18.  
60. Lan KKG DD. Discrete sequential boundaries for clinical trials. Biometrika . 1983;70:659-
663 
61. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics . 
1979;35:549 -556 
62. Kalbfleisch JD PR.  The statistical analysis of failure time data. 2002;2nd Edition:J. Wiley  
 
 